Referências Bibliográficas.
1. GROL, R.;
GRIMSHAW, J. From best evidence to best practice: effective implementation of
change in patients’ care. The Lancet,
London, v. 362, n. 9391, p. 1225-1230, 2003.
2.
W O R
L D H E A L T H O R G A N I Z A T I O N . Medicines:
rational use of medicines. Fact sheet n° 338. May 2010. Disponível em: <http://
www.who.int/mediacentre/factsheets/fs338/en/ print.html> Acesso em: 02 set.
2010.
3.
CONFERENCIA
DE EXPERTOS, 1985, Nairobi. Uso
Racional de Medicamentos. Informe de La Conferencia de Expertos,
Nairobi, 25-29 de noviembre de 1985. Ginebra: Organización Mundial de La Salud,
1986. 304 p.
4.
STRAUS, S. E. et al. Evidence-based medicine: How to practice and
teach EBM. 3 ed. Edinburgh:
Churchill Livingstone, 2005. 299 p.
5. WATERS, E.
et al. Evaluating the efectiveness of public health interventions: the role and
activities of the Cochrane Collaboration. J. Epidemiol. Community Health, London, v. 60, n. 4, p. 285–289,
2006.
6.
VAN, Weel C. Translating research
into practice—a three-paper series. The Lancet, London, v. 362, n. 9391, p. 1170, 2003.
7.
FOR THE GRADE Working Group. Grading
quality of evidence and strength of recommendations. BMJ, London, v. 328, p. 1490, 2004.
8.
FERREIRA,
M. B. C. Fundamentos de Bioestatística: contribuição à Leitura Crítica da
Informação Científica. In: FUCHS, F. D.; WANNMACHER, L. (Eds.). Farmacologia Clínica: Fundamentos da
Terapêutica Racional. 4 ed. Rio de Janeiro: Guanabara Koogan, 2010, p.
26-41.
9.
RYCHETNIK, L. et al. A glossary for
evidence based public health. J. Epidemiol. Community Health, London, v. 58, p. 538–545, 2004. FUCHS,
S. C.; FUCHS, F. D. Métodos de investigação farmacológico-clínica. In: FUCHS,
F. D.; WANNMACHER, L. (Eds.). Farmacologia
Clínica: Fundamentos da Terapêutica Racional. 4 ed. Rio de Janeiro:
Guanabara Koogan, 2010. p. 9-25.
10. KAR, S. S.;
PRADHAN, H. S.; MOHANTA, G. P. Concept of essential medicines and rational use
in public health. Indian. J. Community. Med., [S.l.], v. 35, n. 1, p. 10-13, 2010.
11. BRASIL. Ministério da Saúde. Secretaria de Ciência,
Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e
Insumos Estratégicos. Relação Nacional
de Medicamentos Essenciais: Rename. 7. ed. Brasília, 2010. 250 p.
12. WORLD
HEALTH ORGANIZATION. Continuity and
change: Implementing the 3rd WHO Medicines Strategy (2008–2013). Geneva: WHO, 2008. Disponível em: <http://www.who.
int/medicines/publications/Medicines_Strategy_ draft08-13.pdf> Acesso em: 08
set. 2010.
13. WORLD
HEALTH ORGANIZATION. Essential
Medicines Biennial Report: 2008–2009. Disponível em: <http://www.who.int/medicines/ s16822e.pdf>
Acesso em: 08 set. 2010
14. MCMICHAEL,
C.; WATERS, E.; VOLMINK, J. Evidence-based public health: what does it offer
developing countries? J.Public. Health (Oxf), [S.l.], v. 27, n. 2, p. 215-221, 2005.
15. WORLD
HEALTH ORGANIZATION. The Selection and Use of Essential Medicines. Report of
the WHO Expert Committee, Mar . 2009. WHO
Technical Report Series, Geneva, n. 958, 2009. 231 p.
16. LAING, R.;
HOGERZEIL, H. V.; ROSS-DEGNAN, D. Ten recommendations to improve use of
medicines in developing countries. Health Policy and Planning, Oxford, Inglaterra, v. 16, p. 13-20, 2001.
17. HOGERZEIL,
H. V. The concept of essential medicines: lessons for rich countries. BMJ, London, v. 329, p. 1169-1172, 2004.
18. NEW
medicines in 2007: regulatory agencies and policy makers leave public health in
the hands of the pharmaceutical industry. Prescrire International, [S.l.], v. 17, n. 94, p. 78-82, 2008.
19. SWINGLER,
G. H.; VOLMINK, J.; IOANNIDIS, J. P. A. Number of published systematic reviews
and global burden of disease: database analysis. BMJ, London, v. 327, p. 1083-1084, 2003.
20. GARNER, P.
et al. Putting evidence into practice: how middle and low income countries “get
it together”. BMJ, London, v.
329, p. 1036- 1039, 2004.
21. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Lista DCB - Denominação Comum Brasileira – Consolidada,
2010. Disponível em: <http://www7.anvisa.gov.br/hotsite/farmacopeia/
conteudo/lista_dcb_rdc211_2010.pdf> Acesso em: 14 set. 2010.
22. CHAUDHURY,
R. R. et al. Quality medicines for the poor: experience of the Delhi programme
on rational use of drugs. Health Policy
and Planning, Oxford, Inglaterra, v. 20, n. 2, p. 124– 136, 2005.
23. DAL PIZZOL,
T. S. et al. Adesão
a listas de medicamentos essenciais em municípios de três estados brasileiros. Cad Saúde Pública, Belo Horizonte, v.
26, n. 4, p. 827-836, 2010.
24. PATEL, A.;
GAULD, R.; NORRIS, P.; RADES, T. “This body does not want free medicines”:
South African consumer perceptions of drug quality. Health Policy Plan, Oxford, Inglaterra, v. 25, n. 1, p. 61-69, 2010.
25. TUNIS, S.
R.; STRYER, D. B.; CLANCY, C. M. Practical clinical trials: increasing the
value of clinical research for decision making in clinical and health policy. JAMA, Chicago, Ill., US, v. 290, n. 12, p. 1624-1632, 2003.
26. MUIR GRAY,
J. A. Evidence based policy making. BMJ, London, v. 329, p. 988-989, 2004.
27. GUYATT, G.;
COOK, D.; HAYNES, B. Evidence based medicine has come a long way. BMJ, London, v. 329, p. 990-991, 2004.
28. ESMAIL, L.
C. et al. Framing access to medicines in developing countries: an analysis of
media coverage of Canada’s Access to Medicines Regime. BMC Int Health Hum Rights, [S.l.], v. 10, p. 1, 2010.
29. GREENE, J.
A. When did medicines become essential? Bull
World Health Organ, [S.l.], v. 88, n. 7, p. 483, 2010.
30. GOTTESMAN,
B. S. et al. Impact of quinolone restriction on resistance patterns of
Escherichia coli isolated from urine by culture in a community setting. Clin. Infect. Dis., Chicago, v. 49, p.
869-875, 2009.
31. PATERSON, D. L.; BONOMO, R. A. Extended-spectrum
b-lactamases: a clinical update. Clin.
Microbiol. Rev., Washington, v. 18, p. 657-686, 2005.
32. WANNMACHER, L. Uso indiscriminado de antibióticos e
resistência microbiana: uma guerra perdida? Uso racional de medicamentos: temas selecionados, Brasília, v. 1,
n. 4, mar. 2004. Disponível em: <http://www.opas.org.br/
medicamentos/temas>
33. JENSEN, U.
S. et al. Effect of generics on price and consumption of ciprofloxacin in
primary healthcare: the relationship to increasing resistance. J. Antimicrob. Chemother., [S. l.], v.
65, p. 1286-1291, 2010.
34. COSTELLOE,
C. M. et al. Efect of antibiotic prescribing in primary care on antimicrobial
resistance in individual patients: systematic review and meta-analysis. BMJ, London, v. 340, p. c2096, 2010.
35. LIVERMORE,
D. M. Minimising antibiotic resistance. Lancet.
Infect. Dis., [S. l.], v. 5, p. 450-459, 2005.
36. MACGOWAN,
A. Clinical implications of antimicrobial resistance for therapy. J. Antimicrob. Chemother., [S. l.], v. 62, s. 2, p. 105-114, 2008.
37. DELLIT, T.
H. et al. Infectious disease society of america and the society for healthcare
epidemiology of America guidelines for developing an institutional program to
enhance antimicrobial stewardship. Clin.
Infect. Dis., Chicago, v. 44, p. 159-177, 2007.
38. SEPPALA, H.
et al. The effect of changes in consumption of macrolide antibiotics on
erythromycin resistance in group A streptococci in Finland. N. Engl. J. Med., [S. l.], v. 337, p.
441-446, 1997.
39. ENNE, V. I.
et al. Persistence of sulphonamide resistance in Escherichia coli in the UK
despite national prescribing restriction. Lancet, [S. l.], v. 357, p. 1325-1328, 2001.
40. GOOSSENS,
H. et al. Outpatient antibiotic use in Europe and association with resistance:
a cross-national database study. Lancet,
[S. l.], v. 365, p. 579-587, 2005.
41. BRESSER, P.
et al. Effectiveness of discontinuing antibiotic treatment after three days
versus eight days in mild to moderate-severe community acquired pneumonia:
randomised, double blind study. BMJ,
London, v. 332, p. 1355, 2006.
42. PAKISTAN
MULTICENTRE AMOXYCILLIN SHORT COURSE THERAPY (MASCOT) PNEUMONIA STUDY GROUP.
Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of
childhood pneumonia: a multicentre double-blind trial. Lancet, [S. l.], v. 360, p. 835- 841, 2002.
43. AGARWAL, G.
et al. Three day versus five day treatment with amoxicillin for non-severe
pneumonia in young children: a multicentre randomised controlled trial. BMJ, London, v. 328, p. 791-794, 2004.
44. WARREN, J.
W. et al. Guidelines for antimicrobial treatment of uncomplicated acute
bacterial cystitis and acute pyelonephritis in women. Clin. Infect. Dis., Chicago, v. 29, p. 745-758, 1999.
45. LODISE, T.
P.; LOMAESTRO, B.; DRUSANO, G. L. Piperacillin-tazobactam for Pseudomonas
aeruginosa infection: clinical implications of an extended-dosing strategy. Clin. Infect. Dis., [S. l.], Chicago, v. 44, p. 357-363, 2007.
46. DUNBAR, L.
M. et al. Short-course levofloxacin for community-acquired pneumonia: a new
treatment paradigm. Clin Infect Dis,
Chicago, v. 37, p. 752-760, 2003.
47. PATERSON,
D. L. Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis., Chicago, v. 38, s. 4, p. 341-345, 2004.
48. LAUTENBACH,
E. et al. Extended-spectrum b-lactamase–producing Escherichia coli and
Klebsiella pneumoniae: risk factors for infection and impact of resistance on
outcomes. Clin. Infect. Dis.,
[S. l.], Chicago, v. 32, p. 1 162-1171, 2001.
49. TACCONELLI
E. et al. Does antibiotic exposure increase the risk of methicillin-resistant
Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J. Antimicrob. Chemother., [S. l.], v.
61, p. 26-38, 2008.
50. WANNMACHER, W.; PASSOS, L. F. S. Anti-inflamatórios não
esteroides. In: FUCHS, F. D.; WANNMACHER, L. (Eds.) Farmacologia clínica: fundamentos da terapêutica racional. Rio de
Janeiro: Guanabara Koogan, 2010 p. 408-421.
51. BRASIL. Ministério da Saúde. Secretaria de Ciência,
Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e
Insumos Estratégicos. Relação Nacional
de Medicamentos Essenciais: Rename 2010. 7. ed. Brasília: Ministério da
Saúde. 2010. 250 p.
52. ______. Ministério da Saúde. Agência Nacional de Vigilância
Sanitária (Anvisa). Resolução RDC nº 138, de 29 de maio de 2003. Dispõe sobre o
enquadramento na categoria de venda de medicamentos. Diário Oficial da União, Poder Executivo, Brasília, DF, 02 jun.
2003.
53. WALKER-BONE,
K.; FARROW, S. Rheumatoid arthritis. BMJ Clinical Evidence, 2010. Disponível em:
<http://clinicalevidence.bmj.com/ceweb/index.jsp>
54. SCOTT, D.;
KOWALCZYK, A. Osteoarthritis of the knee. In: Bmj Clinical
Evidence, 2010. Disponível em:
<http://clinicalevidence.bmj.com/ceweb/index.jsp>
55. UNDERWOOD,
M. Gout. In: BMJ Clinical Evidence, 2010.
Disponível em:
<http:// clinicalevidence.bmj.com/ceweb/index.jsp>
56. LANDS, L.
C.; STANOJEVIC, S. Oral non-steroidal anti-inflammatory drug therapy for lung
disease in cystic fibrosis. Cochrane Database of Systematic Reviews. The Cochrane Library, [S. l.], n. 9,
2010. Art. No. CD001505.
57. TOPOL, E.
J. Arthritis Medicines and Cardiovascular Events: House of Coxibs. JAMA, [S. l.], v. 292, n. 24, p. 22-29, 2004.
58. OHLSSON,
A.; WALIA, R.; SHAH, S. S. Ibuprofen for the treatment of patent ductus
arteriosus in preterm and/or low birth weight infants. Cochrane Database of
Systematic Reviews. The Cochrane
Library, [S. l.], n. 9, 2010. Art. No. CD003481.
59. VAITHIANATHAN,
R. et al. Iatrogenic effects of COX-2 inhibitors in the US population: findings
from the Medical Expenditure Panel Survey. Drug Saf., [S. l.], v. 32, p. 335-343, 2009.
60. LEMANSKE
JR., R. F.; BUSSE, W. W. Asthma: clinical expression and molecular mechanisms. J. Allergy Clin. Immunol., [S. l.], v. 125, p. 95-102, 2010.
61. SHAKER, M.
et al. An economic analysis of aspirin desensitization in aspirin-exacerbated
respiratory disease. J. Allergy Clin.
Immunol., [S. l.], v. 121, n. 1, p. 81-87, 2008.
62. GOTZSCHE,
P. C. NSAIDs. In: BMJ Clinical Evidence,
2010. Disponível em:
<http:// clinicalevidence.bmj.com/ceweb/index.jsp>
63. MASSEY, T.
et al. Topical NSAIDs for acute pain in adults. Cochrane Database Syst. Rev., [S. l.], v. 6, jun. 2010. CD007402.
64. SUNG, J.
J.; KUIPERS, E. J.; EL-SERAG, H. B. Systematic review: update on the global
incidence and prevalence of peptic ulcer disease. Aliment. Pharmacol. Ther., [S. l.], v. 29, n. 9, p. 938-946, 2009.
65. COMMITTEE
OF SAFETY OF MEDICINES. Non-steroidal anti-inflammatory drugs (NSAIDs) and
gastrointestinal (GI) safety. Current Problems in
Pharmacovigilance, [S.
l.], v. 28, p. 5, 2002.
66. MASSÓ
GONZÁLEZ, E. L. et al. Variability among nonsteroidal antiinflammatory drugs in
risk of upper gastrointestinal bleeding. Arthritis Rheum, [S. l.], v. 62, n. 6, p. 1592-1601, 2010.
67. FELDMAN, M.
NSAIDs (including aspirin): treatment and secondary prevention of
gastroduodenal toxicity. Up To Date. [S. l.], 2009. Disponível em:
<http://www.uptodateonline.com>.
68. ROSTOM, A.
et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of
Systematic Reviews. The Cochrane
Library, [S. l.], n. 9, 2010. Art. No. CD002296.
69. WANNMACHER, L. Inibidores da bomba de prótons: indicações
racionais. Uso racional de medicamentos:
temas relacionados, Brasília, v. 2, n. 1, 2004. Disponível em:
<http://bvsms.saude.gov. br/bvs/publicacoes/HSE_URM_IBP_1204.pdf >
70.
SPIEGEL, B. M.; CHIOU, C. F.; OFMAN,
J. J. Minimizing complications from nonsteroidal antiinflammatory drugs:
cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum, [S. l.], v. 53, n. 2, p. 185-197, 2005
71. LATIMER, N.
et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs
alone or in combination with a proton pump inhibitor for people with
osteoarthritis. BMJ, London, v.
3369, p.2538, 2009.
72. BROWN, T.
J. et al. A comparison of the cost-effectiveness of five strategies for the
prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal
toxicity: a systematic review with economic modelling. Health Technology Assessment, [S. l.], v. 10, n. 38, p. 1-102, 2006.
73. FOSBØL, E.
L. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs among
healthy individuals. Expert. Opin.
Drug. Saf., [S. l.], v. 9, n. 6, p. 893-903, 2010.
74. KEARNEY, P.
M. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional
non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?
Meta-analysis of randomised trials. BMJ,
London, v. 332, n. 7553, p. 1302-1308, 2006.
75. BUENO, H.
et al. Spanish Case-Control Study to Assess NSAID-Associated ACS Risk
Investigators. Use of non-steroidal antiinflammatory drugs and type-specific
risk of acute coronary syndrome. Am. J. Cardiol., [S. l.], v. 105, n. 8, p. 1102-1106, 2010.
76. FOSBØL, E.
L. et al. Cause-Specific Cardiovascular Risk Associated With Nonsteroidal
Antiinflammatory Drugs Among Healthy Individuals. Circ. Cardiovasc. Qual. Outcomes, [S. l.], v. 3, n. 4, p. 395-405, 2010.
77. .BATLOUNI, M. Nonsteroidal
anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects. Arq. Bras. Cardiol., [S. l.], v. 94, n. 4, p. 556-563, 2010.
78. MORRISON,
A. et al. Systematic review of trials of the effect of continued use of oral
non-selective NSAIDs on blood pressure and hypertension. Current Medical Research e Opinion,
[S. l.], v. 23, n. 10, p. 2395-2404, 2007.
79. CHAN, C. C.
et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs
and placebo? An
updated meta-analysis. J. Hypertens,
v. 27, n. 12, p. 2332-2341, 2009.
80. HUERTA, C.
et al. Nonsteroidal anti-inflammatory drugs and risk of first hospital
admission for heart failure in the general population. Heart, [S. l.], v. 92, n. 11, p. 1610-1615, 2006.
81. SCOTT, P.
A.; KINGSLEY, G. H.; SCOTT, D. L. Non-steroidal anti-inflammatory drugs and
cardiac failure: meta-analyses of observational studies and randomised
controlled trials. Eur. J. Heart Fail, [S. l.], v. 10, n. 11, p. 1102-1107, 2008.
82. HUERTA, C.
et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general
population. Am. J. Kidney Dis.,
[S. l.], v. 45, p. 531-539, 2005.
83. MHRA.
Non-steroidal anti-inflammatory drugs: reminder on renal failure and
impairment. Drug Safety Update, [S. l.], v. 2, n. 10, p. 4, 2009.
84. HOUSE, A.
A.; OLIVEIRA, S. S.; RONCO, C. Anti-inflammatory drugs and the kidney. Int. J. Artif. Organs, [S. l.], v. 30, n. 12, p. 1042-1046, 2007.
85. SCHAEFER,
C.; PETERS, P.; MILLER, R. K. (Eds.). Drugs
during pregnancy and lactation: treatment options and risk assessment. 2. ed. Oxford: Academic Press, 2007.
86. LI, D. K.;
LIU, L.; ODOULI, R. Exposure to non-steroidal anti-inflammatory drugs during
pregnancy and risk of miscarriage: population based cohort study. BMJ, London, v. 327, n. 7411, p. 368-372, 2003.
87. OFORI, B.
et al. Risk of congenital anomalies in pregnant users of non-steroidal
anti-inflammatory drugs: a nested case-control study. Birth Defects Res. B. Dev. Reprod. Toxicol., [S. l.], v. 77, n. 4,
p. 268-279, 2006.
88. NAKHAI-POUR,
H. R.; BERARD, A. Major malformations after first-trimester exposure to aspirin
and NSAIDs. Expert. Rev. Clin. Pharmacol., [S. l.], v. 1, n. 5, p. 605-616, 2008.
89. KOREN, G.
et al. Nonsteroidal antiinflammatory drugs during third trimester and the risk
of premature closure of the ductus arteriosus: a meta-analysis. Ann. Pharmacother., [S. l.], v. 40, n.
5, p. 824-829, 2006.
90. OHLSSON,
A.; WALIA, R.; SHAH, S. S. Ibuprofen for the treatment of patent ductus
arteriosus in preterm and/or low birth weight infants. Cochrane Database of
Systematic Reviews. The Cochrane Library,
[S. l.], n.9., 2010. Art.
No. CD003481.
91. DE VRIES,
F.; SETAKIS, E.; VAN STAA, T. P. Concomitant use of ibuprofen and paracetamol
and the risk of major clinical safety outcomes. Br. J. Clin. Pharmacol, [S. l.], v. 70, n. 3, p. 429-438, 2010.
92. CARDIOVASCULAR
and gastrointestinal safety of NSAIDs. MeReC
Extra, [S. l.], n. 30, p. 1-6, nov. 2007.
93. NATIONAL
INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Osteoarthritis: the care and
management of osteoarthritis in adults. NICE clinical guideline 59, [S. l.], feb. 2008.
94. US FOOD AND
DRUG ADMINISTRATION. Center for Drug Evaluation and Research. New information
for healthcare professionals. Concomitant
use of ibuprofen and aspirin. Disponível em: <http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsand
95. Providers/ucm125222.htm>
96. PAVLIČEVIĆ,
I. et al. Interaction between antihypertensives and NSAIDs in primary care: a
controlled trial. Can. J. Clin.
Pharmacol., [S. l.], v. 15, n. 3, p. 372-382, 2008.
97. ROUGHEAD,
E. E. et al. NSAID use in individuals at risk of renal adverse events: an
observational study to investigate trends in Australian veterans. Drug Saf, [S. l.], v. 31, n. 11, p.
997-1003, 2008.
98. BAXTER, K.
(Ed.). Stockley’s drug interactions:
a source book of interactions, their mechanisms, clinical importance and
management. 7. ed.
London: Pharmaceutical Press, 2006.
99. ACE
inhibitor, diuretic and NSAID: a dangerous combination. Australian Adverse Drug Reactions Bulletin, [S. l.], v. 22, p.
14-16, 2003.
100.
LOKE, Y. K.; TRIVEDI, A. N.; SINGH,
S. Meta-analysis: gastrointestinal bleeding due to interaction between
selective serotonin uptake inhibitors and non-steroidal anti-inflammatory
drugs. Alimentary Pharmacology and Therapeutics, [S. l.], v. 27, n. 1, p. 31-40, 2008.
101.
HEADACHE CLASSIFICATION SUBCOMMITTEE
OF THE INTERNATIONAL HEADACHE SOCIETY. The International Classification of
Headache Disorders. 2 ed. Cephalalgia,
v. 24, supl. 1, p. 8–152, 2004.
102.
GOADSBY, P. J.; LIPTON, R. B.;
FERRARI, M. D. Drug therapy: migraine – current understanding and treatment. New Engl. J. Med. v. 346, p. 257-270, 2002.
103.
LIPTON, R. B.; BIGAL, M. E. The
epidemiology of migraine. Am. J. Med. v. 118, p. 3-10, 2005.
104.
VICTOR, T. W. et al. Migraine
prevalence by age and sex in the United States: a life-span study. Cephalalgia, v. 30, n. 9, p.
1065-1072, 2010.
105.
SILBERSTEIN, S. D. Migraine. Lancet, v. 363, p. 381-391, 2004.
106.
CUVELLIER, J. C. Management of
chronic daily headache in children and adolescents. Rev. Neurol., (Paris) v. 165, n. 6-7, p. 521-531, 2009.
107.
VICTOR, S.; RYAN S. Drugs for
preventing migraine headaches in children. Cochrane Database of Systematic
Reviews. The Cochrane Library,
Issue 9, Art. No. CD002761,
2010.
108.
TIETJEN, G. E. Migraine as a systemic
disorder. Neurology, v. 68, p. 1555-1556, 2007.
109.
SILBERSTEIN, S. D. Meeting acute
migraine treatment needs through novel treatment formulations. Neurotherapeutics, v. 7, n. 2, p. 153-158, 2010.
110.
SCHÜRKS, M. et al. Migraine and
cardiovascular disease: systematic review and meat-analysis. BMJ, v. 339, p. b3914, 2009.
111.
SPECTOR, J. T, Migraine headache and
ischemic stroke risk: an updated meta-analysis. Am. J. Med., v. 123, n. 7, p. 612-624, 2010.
112.
LOVELL, B. V.; MARMURA, M. J. New
therapeutic developments in chronic migraine. Curr. Opin. Neurol., v. 23, n. 3, p. 254-258, 2010.
113.
MELCHART, D. et al. Acupuncture
versus placebo versus sumatriptan for early treatment of migraine attacks: a
randomized controlled trial. J. Intern.
Med., v. 253, p.181-188, 2003.
114.
MILLICHAP, J. G.; YEE, M. M. The diet
factor in pediatric and adolescent migraine. Pediatr. Neurol., v. 28, p. 9-15, 2003.
115.
LINDE, K. Acupuncture for migraine
prophylaxis. Cochrane Database of Systematic Reviews. The Cochrane Library, Issue 10, n. CD001218, 2010.
116.
MULLALLY, W. J. Efficacy of
biofeedback in the treatment of migraineand tension type headaches. Pain Physician, v. 12, p. 1005-1011, 2009.
117.
SUN-EDELSTEIN, C.; MAUSKOP. A. Foods
and supplements in the management of migraine headaches. Clin. J. Pain, v. 25, n. 5, p. 446-452, 2009.
118.
ESPOSITO, M.; CAROTENUTO, M.
Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged
children: an open-label study. Neurol. Sci., Sep 25. [Epub ahead of print], 2010.
119.
SCHIAPPARELLI, P. Non-pharmacological
approach to migraine prophylaxis: part II. Neurol. Sci., v. 31, Suppl 1, S137-139, 2010.
120.
PITTLER, M. H.; ERNST, E. Feverfew
for preventing migraine. Cochrane Database of Systematic Reviews. The Cochrane Library, Issue 9, n. CD002286. 2010.
121.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais:
Rename 2010. 7 ed. Brasília: Ministério da Saúde; 2010. 250 p.
122.
SNOW, V. For the American Academy of
Family Physicians. Pharmacologic management of acute attacks of migraine and
prevention of migraine headache. Ann. Intern. Med., v. 137, p. 840-849, 2002.
123.
WORLD HEALTH ORGANIZATION-WHO. Model Formulary 2008. Disponível em: <http://www.who.int/
selection_medicines/list/en/>. Acesso em 06 out. 2010.
124.
WORLD HEALTH ORGANIZATION-WHO. Model formulary for children 2010:
based on the second model list of essential medicines for children 2009. Geneva: 2010. 500 p. [pdf].
125.
KIRTHI, V. et al. Aspirin with or
without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev., v. 14,
n. 4, CD008041, apr. 2010
126.
PRIOR, M. J.; CODISPOTI, J. R.; FU,
M. A randomized, placebo-controlled trial of acetaminophen for treatment of
migraine headache. Headache, v.
50, n. 5, p.819-833, 2010.
127.
ANNEKEN, K.; EVERS, S.; HUSSTEDT, I.
W. Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and
caffeine in the treatment of idiopathic headache: a review. Eur. J. Neurol., v. 17, n. 4, p. 534-e25 2010.
128.
DIENER, H. C. et al. The fixed
combination of acetylsalicylic acid, paracetamol and caffeine is more effective
than single substances and dual combination for the treatment of headache: a
multicentre, randomized, double-blind, single-dose, placebo-controlled parallel
group study. Cephalalgia, v. 25, n. 10, p. 776-787, 2005.
129.
SUTHISISANG. C. C. Efficacy of
low-dose ibuprofen in acute migraine treatment: systematic review and
meta-analysis. Ann. Pharmacother, v. 41, n. 11, p. 1782-1791, 2007.
130.
SILVER, S. Acute treatment of
paediatric migraine: a meta-analysis of efficacy. J. Paediatr. Child Health, v. 44, n. 1-2, p. 3-9, 2008.
131.
SUTHISISANG. C. C. Meta-analysis of
the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache, v. 50, n. 5, p. 808-818, 2010.
132.
FRIEDMAN, B. W. et al. Treating
headache recurrence after emergency department discharge: a randomized
controlled trial of naproxen versus sumatriptan. Ann. Emerg. Med., v. 56, n. 1, p. 7-17, 2010.
133.
MCCRORY, D. C.; GRAY, R. N. Oral
sumatriptan for acute migraine. Cochrane Database of Systematic Reviews. The Cochrane Library, Issue 10, n.
CD002915. 2010.
134.
TULLO, V. et al. Frovatriptan versus
zolmitriptan for the acute treatment of migraine: a double-blind, randomized,
multicenter, Italian study. Neurol.
Sci., v. 31, Supl. 1, p. S51-54, 2010.
135.
GUIDOTTI, M.; RAVASIO, R. Clinical
and economic comparison of frovatriptan versus other oral triptans in the
treatment of acute migraine in the real-world setting. Clin. Drug Investig., v. 29, n. 11, p. 693-702, 2009.
136.
SILBERSTEIN, SD. Recent developments
in migraine. The Lancet, v. 372, p. 1369-1371, 2008.
137.
SCHULMAN, E. A.; DERMOTT, K. F.
Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache, v. 43, p. 729-733, 2003.
138.
GRIMALDI, D.; CORTELLI, P. Migraine:
treating acute migraine in the emergency department. Nat. Rev. Neurol., v. 5, n. 10, p. 529-531, 2009.
139.
SINGH, A.; ALTER, H. J.; ZAIA, B.
Does the addition of dexamethasone to standard therapy for acute migraine
headache decrease the incidence of recurrent headache for patients treated in
the emergency department? A meta-analysis and systematic review of the
literature. Acad. Emerg. Med., v. 15, n. 12, p. 1223-1233, 2008.
140.
BAILEY, B.; MCMANUS, B. C. Treatment
of children with migraine in the emergency department: a qualitative systematic
review. Pediatr. Emerg. Care, v. 24, n. 5, p. 321-330, 2008.
141.
SCHÜRKS, M.; DIENER, H. C.; GOADSBY
P. Update on the prophylaxis of migraine. Curr. Treat. Options
Neurol., v. 10, n. 1, p. 20-29, 2008.
142.
VICTOR, S., RYAN, S. W. Drugs for
preventing migraine headaches in children. Cochrane Database of Systematic
Reviews. The Cochrane Library,
Issue 10, n. CD002761, 2010.
143.
LINDE, K.; ROSSNAGEL, K. Propranolol
for migraine prophylaxis. Cochrane Database of Systematic Reviews. The Cochrane Library, Issue 10, n. CD003225, 2010.
144.
HOLROYD, K. A. et al. Effect of
preventive (beta blocker) treatment, behavioural migraine management, or their
combination on outcomes of optimised acute treatment in frequent migraine:
randomised controlled trial. BMJ, v.
341, p. c4871, 2010.
145.
JACKSON, J. L. Tricyclic
antidepressants and headaches: systematic review and meta-analysis. BMJ, v. 341, p. c5222. 2010.
146.
MAGALHÃES, E. Botulinum toxin type A
versus amitriptyline for the treatment of chronic daily migraine. Clin. Neurol. Neurosurg., v. 112, n. 6, p. 463-466, 2010.
147.
CHRONICLE, E. P.; MULLENERS, W. M.
Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic
Reviews. The Cochrane Library,
Issue 10, n. CD003226, 2010.
148.
BRANDES,
J. L. et al. Topiramate for migraine prevention: a randomized
controlled trial. JAMA, v. 291, n. 8, p. 965-973, 2004.
149.
SILBERSTEIN, S. et al. Topiramate
treatment of chronic migraine: a randomized, placebo-controlled trial of
quality of life and other efficacy measures. Headache, v. 49, n. 8, p. 1153-1162, 2009.
150.
BIDABADI, E.; MASHOUF, M. A
randomized trial of propranolol versus sodium valproate for the prophylaxis of
migraine in pediatric patients. Paediatr. Drugs, v. 12, n. 4,
p. 269-275, 2010.
151.
SHUHENDLER, A. J. et al. Efficacy of
botulinum toxin type A for the prophylaxis of episodic migraine headaches: a
meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy, v. 29, n. 7, p. 784-791, 2009.
152.
POLANCZYK, C. A.; FURTADO, M. V.; FUCHS,
F. Fármacos utilizados em cardiopatia isquêmica. In: FUCHS, F.; WANNMACHER, L.
(Eds.) Farmacologia clínica:
fundamentos da terapêutica racional. 4. ed. Rio de Janeiro: Guanabara Koogan,
2010. p. 818-842.
153.
YOUNG,
F. et al. Coronary mortality declines in the U.S. between 1980 and 2000
quantifying the contributions from primary and secondary prevention. Am. J. Prev. Med., [S. l.], v. 39, n.
3, p. 228-234, 2010.
154.
POLANCZYK,
C. A.; RIBEIRO, J. P. Coronary artery disease in Brazil: contemporary
management and future perspectives. Heart, [S. l.], v. 95, n. 11, p. 870-876, 2009.
155.
THIRD
Report of the National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III): final report. Circulation, [S. l.], v. 106, n. 25, p. 3143-3421,
2002.
156.
SPOSITO,
A. C. et al. IV Brazilian Guideline for Dyslipidemia and Atherosclerosis
prevention: Department of Atherosclerosis of Brazilian Society of Cardiology. Arq. Bras. Cardiol., [S. l.], v. 88,
s. 1, p. 2-19.
157.
COONEY,
M. T. et al. Assessment of cardiovascular risk. Curr. Hypertens. Rep., [S. l.], v. 12, n. 5, p. 384-393, 2010.
158.
BARROSO, L. C. et al. Performance of the Framingham and SCORE cardiovascular
risk prediction functions in a non-diabetic population of a Spanish health care
centre: a validation study. Scand. J.
Prim. Health Care, sep. 2010. [Epub ahead of print]
159.
GENEST,
J. et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis
and treatment of dyslipidemia and prevention of cardiovascular disease in the
adult - 2009 recommendations. Can. J.
Cardiol., [S. l.], v. 25, n. 10, p. 567-579, 2009.
160.
RAY,
K. K. et al. Statins and all-cause mortality in high-risk primary prevention: a
meta-analysis of 11 randomized controlled trials involving 65,229 participants.
Arch. Intern. Med., [S. l.], v. 170, n. 12, p.
1024-1031, 2010.
161.
FORD,
E. S. et al. Trends in obesity and abdominal obesity among adults in the United
States from 1999-2008. Int. J. Obes.,
London, sep. 2010. [Epub ahead of print]
162.
LAMOTTE,
C. et al. Increased intima-media thickness of the carotid artery in childhood:
a systematic review of observational studies. Eur. J. Pediatr., oct., 2010. [Epub ahead of print]
163.
HOOPER,
L. et al. Omega 3 fatty acids for prevention and treatment of cardiovascular
disease. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 10, 2010. Art.
No. CD003177.
164.
BRASIL. Ministério da Saúde.Secretaria
de Ciência,Tecnologia e Insumos Estratégicos. Departamento de Assistência
Farmacêutica e Insumos Estratégicos. Relação
Nacional de Medicamentos Essenciais: Rename 2010. 7. ed. Brasília:
Ministério da Saúde, 2010.
165.
WENG,
T. C. et al. A systematic review and meta-analysis on the therapeutic
equivalence of statins. J. Clin.
Pharm. Ther., [S. l.], v. 35, n. 2, p. 139-1351, 2010.
166.
MILLS,
E. J. et al. Primary prevention of cardiovascular mortality and events with
statin treatments: a network meta-analysis involving more than 65,000 patients.
J. Am. Coll. Cardiol., [S. l.],
v. 52, n. 22, p. 1769-1781, 2008.
167.
BRUGTS,
J. J. et al. The benefits of statins in people without established
cardiovascular disease but with cardiovascular risk factors: meta-analysis of
randomised controlled trials. BMJ,
[S. l.], v. 338, p. 2376, 2009.
168.
BUKKAPATNAM,
R. N.; GABLER, N. B.; LEWIS, W. R. Statins for primary prevention of
cardiovascular mortality in women: a systematic review and meta-analysis. Prev. Cardiol., [S.l.], v. 13, n. 2,
p. 84-90, 2010.
169.
PETRETTA,
M. et al. Impact of gender in primary prevention of coronary heart disease with
statin therapy: a meta-analysis. Int.
J. Cardiol., [S.l.], v. 138, n. 1, p. 25-31, 2010.
170.
DE CA TERINA, R. et al. Cholesterol-lowering interventions and stroke:
insights from a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol., [S. l.], v .
55, n. 3, p. 198-211, 2010.
171.
RIDKER, P. M. et al. Rosuvastatin to
prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., [S. l.], v. 359, n.
21, p. 2195-2207, 2008.
172.
DE
LORGERIL, M. et al. Cholesterol lowering, cardiovascular
diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch. Intern. Med., [S. l.], v. 170, n. 12, p. 1032-1036, 2010.
173.
KAUL, S.; MORRISSEY, R. P.; DIAMOND,
G. A. By Jove! What is a clinician to make of Jupiter? Arch. Intern. Med., [S. l.], v. 170, n. 12, p. 1073-1077, 2010.
174.
SNOW, V.et al. Lipid control in the
management of type 2 diabetes mellitus: a clinical practice guideline from the
American College of Physicians. Ann.
Intern. Med., [S. l.], v. 140, n. 8, p. 644-649, 2004.
175.
VIJAN, S.; HAYWARD, R. A.
Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background
paper for the American College of Physicians. Ann. Intern. Med., [S. l.], v. 140, n. 8, p. 650-658, 2004.
176.
COSTA, J. et al. Efficacy of lipid
lowering drug treatment for diabetic and non-diabetic patients: meta-analysis
of randomised controlled trials. BMJ,
[S. l.], v. 332, n. 7550, p. 1115-1124, 2006.
177.
NEYT, M. et al. Cost-effectiveness of
statins in the primary prevention of cardiovascular disease: a systematic
review and economic analysis for Belgium. Acta Cardiol, [S. l.], v. 64. n. 1, p.1-10, 2009.
178.
PLETCHER, M. J. et al. Comparing
impact and cost-effectiveness of primary prevention strategies for
lipid-lowering. Ann. Intern. Med.,
[S. l.], v. 150, n. 4, p. 243-254, 2009.
179.
STATIN cost-effectiveness in the
United States for people at different vascular risk levels. Circ. Cardiovasc. Qual. Outcomes, [S. l.], v. 2, n. 2, p. 65-72, 2009.
180.
CLARK, A. M. et al. Meta-analysis:
secondary prevention programs for patients with coronary artery disease. Ann. Intern. Med., [S. l.], v. 143, n.
9, p. 659-672, 2005.
181.
JOSAN, K.; MAJUMDAR, S. R.;
MCALISTER, F. A. The efficacy and safety of intensive statin therapy: a
meta-analysis of randomized trials. CMAJ, [S. l.], v. 178, n. 5, p. 576-584, 2008.
182.
SHENG, X. et al. Statins and total
(not LDL) cholesterol concentration and outcome of myocardial infarction:
results from a meta-analysis and an observational study. Eur. J. Clin. Pharmacol., [S. l.], v.
65, n. 11, p. 1071- 1080, 2009.
183.
AFILALO, J. et al. Statins for
secondary prevention in elderly patients: a hierarchical bayesian
meta-analysis. J. Am. Coll. Cardiol,
[S. l.], v. 51, n. 1, p. 37-45, 2008.
184.
AMARENCO, P. et al. High-dose
atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med., [S. l.], v. 355, n. 6, p. 549-559, 2006.
185.
NICHOLLS, S. J. et al. Meta-analysis
of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin
versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am. J. Cardiol., [S. l.], v. 105, n.
1, p. 69-76, 2010.
186.
GRAY, J.; EDWARDS, S. J.; LIP, G. Y.
Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a
meta-analysis of randomised controlled trials. Curr. Med. Res. Opin., [S. l.], v. 26, n. 3, p. 537-547, 2010.
187.
SCHUSTER, H. The GALAXY Program: an
update on studies investigating efficacy and tolerability of rosuvastatin for
reducing cardiovascular risk. Expert. Rev. Cardiovasc. Ther., [S. l.], v. 5, n. 2, p. 177-193, 2007.
188.
HALL, A. S. et al. A randomized,
controlled trial of simvastatin versus rosuvastatin in patients with acute
myocardial infarction: the Secondary Prevention of Acute Coronary
Events--Reduction of Cholesterol to Key European Targets Trial. Eur. J. Cardiovasc. Prev. Rehabil., [S. l.], v. 16, n. 6, p. 712-721, 2009.
189.
PICON,
P. D. Comunicação pessoal.
Acesso em: 05. nov. 2010. Texto constante dos novos protocolos clínicos do
Ministério da Saúde, ainda não publicados.
190.
WARD, S. et al. A systematic review
and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess., [S. l.], v.
11, n. 14, p. 1-160, 2007.
191.
MARTIKAINEN, J. E. et al. Impact of
restricted reimbursement on the use of statins in Finland: a register-based
study. Med. Care, [S. l.], v.
48, n. 9, p. 761-766, 2010.
192.
VERHAGEN, A. P. et al. Treatment of
tension type headache: paracetamol and NSAIDs work: a systematic review. Ned. Tijdschr. Geneeskd., [S. l.], v.
154, A1924, 2010.
193.
FERREIRA,
M. B. C. Princípios gerais no tratamento de dor. In: FUCHS, F. D.; WANNMACHER, L.
(Eds.) Farmacologia Clínica:
fundamentos da terapêutica racional. 4. ed. Rio de Janeiro: GEN/Guanabara
Koogan, 2010. p. 214-230.
194.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais:
Rename 2010. 7. ed. Brasília: Ministério da Saúde, 2010. 250 p.
195.
ONG, C. K. S. et al. An
evidence-based update on nonsteroidal anti-inflammatory drugs. Clin. Med. Res., [S. l.], v. 5, n. 1, p. 19-34, 2007.
196.
SACHS, C. J. Oral analgesics for
acute nonspecific pain. Am. Fam. Phys.,
[S. l.], v. 71, p. 913-918, 2005.
197.
TOMS, L. et al. Single dose oral
paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database
of Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD004602.
198.
WEIL, K. et al. Paracetamol for pain
relief after surgical removal of lower wisdom teeth. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD004487.
199.
ROELOFS, P. D. D. M. et al.
Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD000396.
200.
BUCKLEY, N.; EDDLESTON, M.
Paracetamol (acetaminophen) poisoning. In.: BMJ Clinical Evidence, 2010. Web publication date: 04 Dec 2007
(based on March 2007 search).
201.
MATTIA, C.; COLUZZI, F. What
anesthesiologists should know about paracetamol (acetaminophen). Minerva Anestesiol, [S. l.], v. 75, n. 11, p. 644-653, 2009.
202.
OSCIER, C. D.; MILNER, Q. J. W.
Peri-operative use of paracetamol. Anaesthesia, [S. l.], v. 64, p. 64-72, 2009.
203.
WANNMACHER,
L. Paracetamol versus dipirona: como mensurar o risco? In: Opas. Uso racional de medicamentos: temas
selecionados, Brasília, v. 2, n. 5, abril 2005.
204.
DERRY, C. et al. Single dose oral
ibuprofen for acute postoperative pain in adults. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD001548.
205.
WAHBA, H. The antipyretic effect of
ibuprofen and acetaminophen in children. Pharmacotherapy, [S. l.], v. 24, p. 280-284, 2004.
206.
EDWARDS, J. et al. Single dose oral
aspirin for acute pain. Cochrane Database of Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD002067.
207.
EDWARDS, J. et al. Single dose
dipyrone for acute postoperative pain. Cochrane Database of Systematic Reviews.
In: The Cochrane Library, Issue
10, 2010. Art.
No. CD003227.
208.
RAMACCIOTTI, A. S.; SOARES, B.;
ATALLAH, A. N. Dipyrone for acute primary headaches. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD004842.
209.
EDWARDS, J. et al. Single dose
dipyrone for acute renal colic pain. Cochrane Database of Systematic Reviews.
In: The Cochrane Library, Issue
10, 2010. Art.
No. CD003867.
210.
HAMERSCHLAK, N.; CAVALCANTI, A.B.
Neutropenia, agranulocytosis and dipyrone. Med. J., São Paulo, v. 123, n. 5, p.247-249, 2005.
211.
IBANEZ, L. et al. Agranulocytosis
associated with dipyrone (metamizol). Eur.
J. Clin. Pharmacol., [S. l.], v. 60, n. 11, p. 821-829, 2005.
212.
IBANEZ, L. et al. Population-based
drug-induced agranulocytosis. Arch.
Intern. Med., [S. l.], v. 165, n. 8, p. 869-874, 2005.
213.
SCHONHOFER, P. S. Dipyrone
(Metamizol): Restored to Good Reputate? Internistiche Praxis, [S. l.], v. 39, p. 184-185, 1999. Disponível em:
<http:// www. sobravime.org.br/disc_dipirona.html>
214.
SCHÜLER-FACCINI, L. et al. Dipyrone
use during pregnancy and adverse perinatal events. Arch. Gynecol. Obstet., [S. l.], v. 279, n. 3, p. 293-297, 2009.
215.
FERREIRA,
M. B. C. Analgésicos não opioides. In: FUCHS, F. D.; WANNMACHER, L.
(Eds.) Farmacologia Clínica:
fundamentos da terapêutica racional. 4. ed. Rio de Janeiro: GEN/Guanabara
Koogan, 2010. p. 342-378.
216.
MCQUAY, H. J.; MOORE, R. A. Dose-response
in direct comparisons of different doses of aspirin, ibuprofen and paracetamol
(acetaminophen) in analgesic studies. Br.
J. Clin. Pharmacol., [S. l.], v. 63, n. 3, p. 271-278, 2007.
217.
MELLO,
E. D. de. Prescrição de medicamentos em pediatria. In: FUCHS,
F. D.; WANNMACHER, L. (Eds.) Farmacologia clínica: fundamentos da terapêutica racional. 4. ed. Rio de Janeiro:
GEN/ Guanabara Koogan, 2010. p. 1160-1168.
218.
GILARDÓN,
E. O. A. La fiebre es solo hipertermia? Boletín
PROAPS – Remediar, [S. l.], v. 2, n. 12, 2004. Disponível em:
<www.femeba.org.ar/ fundacion>,. Acesso em:24 nov. 2010.
219.
ANTIPYRETIC drugs for children. BMJ, [S. l.], v. 333, p. 3-5, 2006.
220.
MEREMIKWU, M.; OYO-ITA, A.
Paracetamol versus placebo or physical methods for treating fever in children.
Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 10, 2010. Art. No. CD003676.
221.
ALVES, J. G.; ALMEIDA, N. D.;
ALMEIDA, C. D. Tepid sponging plus dipyrone versus dipyrone alone for reducing
body temperature in febrile children. Med. J., São Paulo, v. 126, n. 2, p. 107-111, 2008.
222.
WANNMACHER,
L.; FERREIRA, M. B. C. Febre: mitos que determinam condutas. In: Farmacoterapia baseada em evidências:
temas selecionados, Brasília, v.1, n. 9, ago. 2004. Disponível em:
<www.opas.org.br/ medicamentos/urm e www.saude.gov.br/sctie>. Acesso em:
24 nov. 2010.
223.
BURKE, A.; SMYTH, E. M.; FITZGERALD,
G. A. Analgesic-antipyretic agents; pharmacotherapy of gout. In: BRUNTON, L.
L.; LAZO, J. S.; PARKER, K. L. (Eds.). Goodman
& Gilman´s the pharmacological basis of therapeutics. 11. ed. New
York: McGraw-Hill, 2006. p. 671-715.
224.
PIERCE, C. A.; VOSS, B. Efficacy and
safety of ibuprofen and acetaminophen in children and adults: a meta-analysis
and qualitative review. Ann. Pharmacother, [S. l.], v. 44. n. 3, p. 489-506, 2010.
225.
SOUTHEY, E. R.; SOARES-WEISER, K.;
KLEIJNEN, J. Systematic review and meta-analysis of the clinical safety and
tolerability of ibuprofen compared with paracetamol in paediatric pain and
fever. Curr. Med. Res. Opin., [S. l.], v. 25, n. 9,
p. 2207-2222, 2009.
226.
KOKKI, H.; KOKKI, M. Ketoprofen
versus paracetamol (acetaminophen) or ibuprofen in the management of fever:
results of two randomized, double-blind, double-dummy, parallel-group,
repeated-dose, multicentre, phase III studies in children. Clin. Drug Investig, [S. l.], v. 30, n. 6, p. 375-386, 2010.
227.
WONG, A. et al. Fever Pediatric Study
Group. Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in
children: results of a multinational, randomized, modified double-blind study. Clin. Pediatr., [S.l.], v. 40, p. 313-324, 2001.
228.
GOZZOLI, V. et al. Randomized trial
of the effect of antipyresis by metamizol, propacetamol or external cooling on
metabolism, hemodynamics and inflammatory response. Intensive Care Med., [S. l.], v. 30, p. 401-407, 2004.
229.
DIAZ-QUIJANO,
F. A.; VILLAR-CENTENO, L. A.; MARTÍNEZ-VEJA, R. A. Effecto de la administración
temprana de dipirona sobre la gravedad del dengue en una cohorte prospectiva.
Enferm. Infec. Microbiol. Clin.,
[S. l.], v. 23, n. 10, p. 593-597, 2005.
230.
MAYORAL, C. E. et al. Alternating
antipyretics: is this an alternative? Pediatrics,
[S. l.], v. 105, p. 1009-1012, 2000.
231.
KRAMER, L. C. et al. Alternating
antipyretics: antipyretic efficacy of acetaminophen versus acetaminophen
alternated with ibuprofen in children. Clin.
Pediatr., [S. l.], v. 47, n. 9, p. 907-911, 2008.
232.
HAY, A. D. et al. Paracetamol and
ibuprofen for the treatment of fever in children: the PITCH randomised
controlled trial. Health Technol.
Assess., [S. l.], v. 13, n. 27, p. 1-163, 2009.
233.
HOLLINGHURST, S. et al. Paracetamol
plus ibuprofen for the treatment of fever in children (PITCH): economic
evaluation of a randomised controlled trial. BMJ, [S. l.], v. 337, p. a1490, 2008.
234.
HEMAL, A.; KALRA, B. P.; GUPTA, V.
Febrile seizures. J. Indian. Med.
Assoc., [S. l.], v. 108, n. 1, p. 36-38, 2010.
235.
LUX, A. L. Treatment of febrile
seizures: historical perspective, current opinions, and potential future
directions. Brain Dev., [S. l.], v. 32, n. 1, p. 42-50, 2010.
236.
STRENGELL, T. et al. Antipyretic
agents for preventing recurrences of febrile seizures: randomized controlled
trial. Arch. Pediatr. Adolesc. Med.,
[S. l.], v. 163, n. 9, p. 799-804, 2009.
237.
BENAZZI, F. Classifying mood
disorders by age-at-onset instead of polarity. Prog. Neuropsychopharmacol Biol. Psychiatry, [S. l.], v. 33, p.
86–93, 2009.
238.
ROY-BYRNE, P. P. et al. Low
socioeconomic status and mental health care use among respondents with anxiety
and depression in the NCS-R. Psychiatr.
Serv., [S. l.], v. 60, p. 1190– 1197, 2009.
239.
SEEDAT, S. et al. Cross-national
associations between gender and mental disorders in the World Health
Organization World Mental Health Surveys. Arch Gen Psychiatry, [S. l.], v. 66, p. 785–795, 2009.
240.
NOCK, M. K. et al. Cross-national
analysis of the associations among mental disorders and suicidal behavior:
findings from the WHO World Mental Health Surveys. PLOS. Med., [S. l.], v. 6, p. e1000123, 2009.
241.
PAYNE, N. A.; PRUDIC, J.
Electroconvulsive therapy: part II: a biopsychosocial perspective. J. Psychiatr. Pract., [S. l.], v. 15, p. 369–390, 2009.
242.
BARBUI, C. et al. Depression in
adults: drug and physical treatments. In.: BMJ Clinical Evidence 2010. Web publication date: 15 Jun 2007
(based on April 2006 search).
243.
MEAD, G. E. et al. Exercise for
depression. Cochrane Database of Systematic Reviews. In: The Cochrane
Library, n. 10, 2010. Art. No. CD004366.
244.
BUTLER, R. et al. Depression in
adults: psychological treatments and care pathways. BMJ Clinical Evidence 2009. Web publication date: 15 Aug 2007
(based on April 2006 search).
245.
GARBER, J. et al. Prevention of
Depression in At-Risk Adolescents. A Randomized Controlled Trial. JAMA, [S. l.], v. 301, n. 2215-2224,
2009.
246.
CUIJPERS, P. et al. Psychological
treatment of depression in primary care: a meta-analysis. Br. J. Gen. Pract., [S. l.], v. 59, n.
559, p. e51–60, 2009.
247.
SARRIS, J.; KAVANAGH, D. J. Kava and
St. John’s wort: current evidence for use in mood and anxiety disorders. J. Altern. Complement. Med., [S. l.], v. 15, p. 827–836, 2009.
248.
LINDE, K.; BERNER, M. M.; KRISTON, L.
St John’s wort for major depression. Cochrane Database of Systematic Reviews.
In: The Cochrane Library, n. 10,
2010. Art. No. CD000448.
249.
RAHIMI, R.; NIKFAR, S.; ABDOLLAHI, M.
Efficacy and tolerability of hypericum perforatum in major depressive disorder
in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog. Neuropsychopharmacol Biol.
Psychiatry, [S.
l.], v. 33, n. 1, p. 118-127, 2009.
250.
HOU, W. H. et al. Treatment effects
of massage therapy in depressed people: a meta-analysis. J. Clin. Psychiatry, [S. l.], v. 71,
n. 7, p. 894–901, 2010.
251.
WANNMACHER,
L. Antidepressivos e lítio. In: FUCHS, F. D.; WANNMACHER, L. Farmacologia clínica: fundamentos da
terapêutica racional. 4. ed. Rio de Janeiro: GEN/Guanabara Koogan, 2010. p.
741–757.
252.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais:
Rename 2010. 7. ed. Brasília: Ministério da Saúde. 2010. 250 p.
253.
TOHEN, M. et al.
Olanzapine/fluoxetine combination in patients with treatment-resistant
depression: rapid onset of therapeutic response and its predictive value for
subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry, [S. l.], v. 71,
n. 4, p. 451–462, 2010.
254.
ARROLL, B. et al. Antidepressants
versus placebo for depression in primary care. Cochrane Database of Systematic
Reviews. In: The Cochrane Library,
n. 10, 2010. Art.
No. CD007954.
255.
GUAIANA, G.; BARBUI, C.; HOTOPF, M.
Amitriptyline for depression. Cochrane Database of Systematic Reviews. In: The Cochrane
Library, n. 10, 2010. Art. No. CD004186.
256.
CIPRIANI, A. et al. Fluoxetine versus
other types of pharmacotherapy for depression. Cochrane Database of Systematic
Reviews. In: The Cochrane Library, n.
10, 2010. Art.
No. CD004185.
257.
STONE, M. et al. Risk of suicidality
in clinical trials of antidepressants in adults: analysis of proprietary data
submitted to US Food and Drug Administration. BMJ, [S. l.], v. 339, p. b2880, 2009.
258.
HAZELL, P. Depression in children and
adolescents. In: BMJ Clinical Evidence
2010. Web publication date: 7 Jan 2009 (based on April 2008 search).
259.
MAYOR, S. Psychological therapy must
accompany antidepressants in young people. BMJ, [S. l.], v. 331, p. 714, 2005.
260.
BRIDGE, J. A. et al. Clinical
response and risk for reported suicidal ideation and suicide attempts in
pediatric antidepressant treatment: a meta-analysis of randomized controlled
trials. JAMA, [S. l.], v. 297,
p. 1683–1696, 2007.
261.
HETRICK, S. et al. Selective
serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and
adolescents. Cochrane Database of Systematic Reviews. In: The Cochrane Library, n. 10, 2010. Art. No. CD004851.
262.
CRAIG, M.; HOWARD, L. Postnatal
depression. In: BMJ Clinical Evidence
2009. Web publication date: 26 Jan 2009 (based on May 2008 search).
263.
WANNMACHER,
L. Depressão perinatal. Farmacoterapia Baseada em Evidência. Temas selecionados, Brasília, OPAS,
v.4, n. 11, 2007. Disponível em: <http://www.opas.org.br/medicamentos/
temas_documentos>. Acesso em: 8 dez. 2010.
264.
MORRELL, C. J. et al. Clinical
effectiveness of health visitor training in psychologically informed approaches
for depression in postnatal women: pragmatic cluster randomised trial in
primary care. BMJ, [S. l.], v.
338, p. a 3045, 2009.
265.
BARCELOS-FERREIRA,
R. et al. Depressive morbidity and gender in community-dwelling
Brazilian elderly: systematic review and meta-analysis. Int. Psychogeriatr., [S. l.], v. 22, n. 5,
p. 712–726, 2010.
266.
HUANG, C. Q. et al. Chronic diseases
and risk for depression in old age: a meta-
267.
analysis of published literature. Ageing Res. Rev., [S. l.], v. 9, n. 2, p. 131–141, 2010.
268.
CHANG-QUAN, H. et al. Health status
and risk for depression among the elderly: a meta-analysis of published
literature. Age Ageing, [S. l.],
v. 39, n. 1, p. 23–30, 2010.
269.
HATTORI, H. Depression in the
elderly. Nippon Ronen Igakkai Zasshi,
[S. l.], v. 45, p. 451–461, 2008.
270.
PERPÉTUO,
I.H.O.; WONG, L.L.R. Desigualdade socioeconômica na utilização de métodos
anticoncepcionais no Brasil: uma análise comparativa com base nas PNDS 1996 e
2006. In: BRASIL. Ministério da Saúde. Pesquisa
Nacional de Demografia e Saúde da Criança e da Mulher - PNDS 2006:
dimensões do processo reprodutivo e da saúde da criança. Brasília, DF:
Ministério da Saúde, 2009. p. 87-104. Disponível em: <http://
bvsms.saude.gov.br/bvs/publicacoes/pnds_ crianca_mulher.pdf>. Acesso em: 10
out. 2010.
271.
BRASIL.
Ministério da Saúde. Secretaria de Atenção à Saúde. Área Técnica de Saúde da
Mulher. Direitos sexuais e direitos
reprodutivos: uma prioridade do governo. Brasília, DF, 2005. 24 p.
272.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação nacional de medicamentos essenciais:
Rename 2010. 7 ed. Brasília, DF, 2010. 250 p.
273.
AMY, J-J.; TRIPATHI, V. Contraception
for women: an evidence based overview. BMJ, London, n. 339, p. b2895, 2009.
274.
HEINEMANN, L.A. et al. Use of oral
contraceptives containing gestodene and risk of venous thromboembolism: outlook
10 years after the third-generation “pill scare”. Contraception, Stoneham , v. 81, n. 5, p. 401-407, 2010.
275.
VAN VLIET, H. A.A.M. et al. Biphasic
versus monophasic oral contraceptives for contraception. Cochrane Database of Systematic Reviews,
Oxford, Issue 10, 2010. Art. No. CD002032.
276.
VAN VLIET, H. A.A.M. et al. Biphasic
versus triphasic oral contraceptives for contraception. Cochrane Database of Systematic Reviews, Oxford, Issue 10, 2010.
Art. No. CD003283. 2006,
Issue 3. Art. No. CD003283.
277.
LUBIANCA,
J.N. Anticoncepcionais orais. In: FUCHS F.D.; WANNMACHER, L. (Ed). Farmacologia clínica: fundamentos da terapêutica racional. 4 ed. Rio de Janeiro:
Guanabara Koogan, 2010. p. 1040-1052.
278.
BACHMANN, G; KORNER P. Bleeding
patterns associated with oral contraceptive use: a review of the literature. Contraception, Stoneham, n. 76, p. 182-189, 2007.
279.
FARQUHAR, C.; BROWN, J. Oral
contraceptive pills for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, Oxford, Issue 10, 2010.
Art. No. CD000154.
280.
WONG, C.L. Et al. Oral contraceptive
pill for primary dysmenorrhoea. Cochrane
Database of Systematic Reviews. Oxford, Issue 10, 2010. Art. No.
CD002120.
281.
MAIA, H.J.; CASOY, J. Non-contraceptive
health benefits of oral contraceptives. Eur. J. Contracept. Reprod. Health Care, New York, v. 13, p.17-24,
2008.
282.
HANNAFORD, P.C. et al. Cancer risk
among users of oral contraceptives: cohort data from the Royal College of
General Practitioner’s oral contraception study. BMJ, London, v. 335, n. 7621, p. 651, 2007.
283.
AROWOJOLU, A.O. et al. Combined oral
contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews. Oxford, Issue 10, 2010.
Art. No. CD004425.
284.
PALOMBO-KINNE, E. et al. Efficacy of
a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg
dienogest for the treatment of papulopustular acne in comparison with placebo
and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception, Stoneham, n. 79, p. 282-289, 2009.
285.
ESCOBAR-MORREALE, H.F. Diagnosis and
management of hirsutism. Ann. N. Y.
Acad. Sci., New York, n. 1205, p. 166-174, 2010.
286.
AMERICAN COLLEGE OF OBSTETRICIANS AND
GYNECOLOGISTS. ACOG Practice Bulletin No. 73: Use of hormonal contraception in
women with coexisting medical conditions. Obstetrics and Gynecology, New York, n. 107, p.1453-1472, 2006.
287.
WORLD HEALTH ORGANIZATION. Medical eligibility criteria for
contraceptive use. 3 ed. Geneva: WHO Reproductive Health and Research, 2004. 154 p.
288.
SEIBERT, C. et al. Prescribing oral
contraceptives for women older than 35 years of age.A nnals of Internal Medicine, Philadelphia, n. 138, p. 54-64,
2003.
289.
VAN HYLCKAMA VLIEG, A. et al. The
venous thrombotic risk of oral contraceptives, effects of oestrogen dose and
progestogen type: results of the MEGA case-control study. BMJ, London, n. 339, p. b2921, 2009.
290.
KEMMEREN, J.M.; ALGRA, A.; GROBBEE,
D.E. Third generation oral contraceptives and risk of venous thrombosis:
meta-analysis. BMJ, London, n.
323, p. 131-134, 2001.
291.
PARSEY, K.S.; PONG, A. An open-label,
multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive
containing drospirenona, a new progestogen. Contraception, Stoneham, n. 61, p. 105-111, 2000.
292.
HUBER J. et al. Efficacy and tolerability
of a monophasic oral contraceptive containing ethinylestradiol and
drosperinone. Eur. J. Contracept.
Reprod. Health Care, New York, n. 5, p. 25-34, 2000.
293.
LUBIANCA, J.N.; FACCIN, C.S.; FUCHS,
F.D. Oral contraceptives: a risk factor for uncontrolled blood pressure among
hypertensive women. Contraception, Stoneham, n. 67, p. 19-24, 2003.
294.
LUBIANCA, J.N. et al. Stopping oral
contraceptives: an effective blood pressure lowering intervention in women with
hypertension. Journal of Human
Hypertension, London, n. 19, p. 451- 455, 2005.
295.
MARTINS, S.L.; CURTIS, K.M.; GLASIER,
A.F. Combined hormonal contraception and bone health: a systematic review. Contraception, Stoneham , v. 73, p. 445-469, 2006.
296.
BEKSINSKA, M.E. et al. Bone mineral
density in a cohort of adolescents during use of norethisterone enanthate,
depot-medroxyprogesterone acetate or combined oral contraceptives and after
discontinuation of norethisterone enanthate. Contraception, Stoneham , v. 79, p. 345-349, 2009.
297.
BERENSON, A.B. et al. Effects of
hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol, [S.l.], v. 103, n. 59,
p. 899-906, 2004.
298.
HARTARD, M. et al. Comparison of the
skeletal effects of the progestogens desogestrel and levonorgestrel in oral
contraceptive preparations in young women: controlled, open, partly randomized
investigation over 13 cycles. Contraception,
Stoneham , v. 74, p. 367-375, 2006.
299.
CIBULA, D. et al. Hormonal
contraception and risk of cancer. Hum.
Reprod. Update, Oxford, v. 16, n. 6, p. 631-650, 2010.
300.
HANNAFORD, P.C. et al. Mortality
among contraceptive pill users: cohort evidence from Royal College of General
Practitioners’ Oral Contraception Study. BMJ, London, v. 340, p. c927, 2010.
301.
GRIMES, D.A. et al. Progestin-only
pills for contraception. Cochrane
Database of Systematic Reviews, Oxford, Issue 1, 2010. Art. No. CD007541.
302.
KJOS, S.L. Contraception and the risk
of type 2 diabetes mellitus in latin women with prior gestational diabetes
mellitus. JAMA, Chicago, n. 280, p. 533- 538, 1998.
303.
WANNMACHER,
L. Contracepção de emergência: evidências versus preconceitos. Uso Racional de Medicamentos: temas
selecionados. Brasília, DF, v. 2, n. 6, maio 2005. Disponível em: <
http://www.opas.org.br/medicamentos/site/
304.
uploadArq/HSE_URM_COE_0505.pdf
>. Acesso em: 10 dez. 2010.
305.
VON HERTZEN, H. et al. Low dose
mifepristone and two regimens of levonorgestrel for emergency contraception: a
WHO multicentre randomised trial. Lancet,
London, n. 360, p. 1803- 1810, 2002.
306.
HALPERN, V.; RAYMOND, E.G.; LOPEZ,
L.M. Repeated use of pre- and postcoital hormonal contraception for prevention
of pregnancy. Cochrane Database of
Systematic Reviews, Oxford, Issue 1, 2010. Art. No. CD007595.
307.
MARSTON, C.; MAJEED, A. Impact on
contraceptive practice of making emergency hormonal contraception available
over the counter in Great Britain: repeated cross sectional surveys. BMJ, London, v. 331, p. 271, 2005.
308.
SCHREIBER, C.A.; RATCLIFFE, S.J.;
BARNHART, K.T. A randomized controlled trial of the effect of advanced supply
of emergency contraception in postpartum teens: a feasibility study. Contraception, Stoneham, v. 81, n. 5, p. 435-440, 2010.
309.
LEWINGTON, S. et al. Age-specific
relevance of usual blood pressure to vascular mortality: a meta-analysis of
individual data for one million adults in 61 prospective studies. Lancet, London, n. 360, p. 1903- 1913,
2002. Prospective Studies Collaboration.
310.
MOREIRA,
L.B. et al. Incidence of hypertension in Porto Alegre, Brazil: a
population-based study. Journal of
Human Hypertension, London, n. 22, p. 48-50, 2008.
311.
FUCHS, F.D. Blood pressure-lowering
drugs: essential therapy for some patients with normal blood pressure. Expert Review of Cardiovascular
Therapy, London, n. 2, p.
771-775, 2004.
312.
FUCHS, F.D. Diuretics: still
essential drugs for the management of hypertension. Expert Review of Cardiovascular
Therapy, London, n. 7, p.
591- 598, 2009.
313.
FUCHS,
F.D. Anti-hipertensivos. In: FUCHS, F.D.; WANNMACHER, L. (Ed.)
Farmacologia clínica:
fundamentos da terapêutica racional. Rio de Janeiro: Guanabara Koogan, 2010. p.
843-861.
314.
LAW, M.R.; MORRIS; J.K., WALD, N.J.
Use of blood pressure lowering drugs in the prevention of cardiovascular
disease: meta-analysis of 147 randomised trials in the context of expectations
from prospective epidemiological studies. BMJ, London, n. 338, p. B1665, 2009
315.
FUCHS, F.D. Prehypertension: the
rationale for early drug therapy. Cardiovascular Therapeutics, [S.l.], v. 28, n. 6, p. 339-343, 2010.
316.
FUCHS, F.D. The corporate bias and
the molding of prescription practices: the case of hypertension. Brazilian Journal of Medical and Biological
Research, Ribeirão Preto, n. 42, p. 224-228, 2009.
317.
THE ANTIHYPERTENSIVE and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes
in high-risk hypertensive patients randomized to angiotensin-converting enzyme
inhibitor or calcium channel blocker vs. diuretic. JAMA, Chicago, n. 288, p. 2981-2997, 2002. The ALLHAT
Collaborative Research Group.
318.
RAHMAN, M. et al. Renal outcomes in
high-risk hypertensive patients treated with an angiotensinconverting enzyme
inhibitor or a calcium channel blocker vs a diuretic: a report from the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Archives of Internal Medicine, Chicago, n. 165, p. 936-946,
2005.
319.
BARZILAY, J.I. et al. Fasting glucose
levels and incident diabetes mellitus in older nondiabetic adults randomized to
receive 3 different classes of antihypertensive treatment: a report from the
Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Archives of Internal Medicine,
Chicago, n. 166, p. 2191-2201, 2006.
320.
FUCHS, F.D. Corporate influence over
planning and presentation of clinical trials: beauty and the beast. Expert Review of Cardiovascular
Therapy, London, n. 8, p.
7-9, 2010.
321.
LAW, M.R.; MORRIS, J.K.; WALD, N.J.
Lowering blood pressure to prevent myocardial infarction and stroke: a new
preventive strategy. Health Technology Assessment, Rockville, n. 7, p. 1-94, 2003.
322.
YUSUF, S. et al. Telmisartan,
ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine,
Boston, n. 358, p. 1547-1559, 2008. Ontarget Investigators.
323.
JAMERSON, K. et al. Benazepril plus
amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine,
Boston, n. 359, p. 2417-2428, 2008.
324.
FUCHS, F.D.; GUERRERO, P.; GUS, M.
What is next when the first blood pressure-lowering drug is not sufficient? Expert Review of Cardiovascular
Therapy, London, n. 5, p.
435-439, 2007.
325.
GUERRERO, P. et al. Blood
pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in
patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clinical and Experimental Hypertension,
New York,
326.
n. 30,
p. 553-564, 2008.
327.
HANSSON, L. et al. Effects of
intensive blood-pressure lowering and low-dose aspirin in patients with
hypertension: principal results of the Hypertension Optimal Treatment (HOT)
randomised trial. HOT Study Group. Lancet,
London, n. 351, p. 1755-1762, 1998.
328.
CUSHMAN, W.C. et al. Effects of
intensive blood-pressure control in type 2 diabetes mellitus. New England Journal of Medicine,
Boston, n. 362, p. 1575-1585, 2010. The ACCORD Study Group.
329.
ABALOS, E. et al. Antihypertensive
drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews,
Oxford, Issue 1, 2007. CD002252.
330.
DULEY, L., HENDERSON-SMART, D.J.;
MEHER, S. Drugs for treatment of very high blood pressure during pregnancy.Cochrane Database of Systematic Reviews,
Oxford, Issue 3, 2006. CD001449.
331.
CASTRO,
M.S. et al. Pharmaceutical care program for patients with
uncontrolled hypertension. Report of a double-blind clinical trial with
ambulatory blood pressure monitoring. American Journal of Hypertension, New York, n. 19, p. 528-533, 2006.
332.
GONÇALVES, C.B. et al. Adverse events
of blood-pressure-lowering drugs: evidence of high incidence in a clinical
setting. European Journal of Clinical
Pharmacology, New York, n. 63, p. 973- 978, 2007.
333.
NEATON. J.D. et al. Treatment of Mild
Hypertension Study (TOMHS): final results. JAMA, Chicago, n. 270, p. 713-724, 1993.
334.
SIPAHI, I. et al.
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised
controlled trials. Lancet Oncology,
London, n.11, p. 627-636, 2010.
335.
WOLFF,
F.H.; BRANDÃO, A.B.M. Fármacos usados em úlcera péptica e doença do refluxo
gastresofágico. In: FUCHS, F.D.; WANNMACHER, L. (Ed). Farmacologia clínica: fundamentos da terapêutica racional. 4 ed.
Rio de Janeiro: GEN/Guanabara Koogan, 2010. p. 966-978.
336.
LACY, C.F. et al. Drug information handbook international:
2006-2007. 14 ed. Hudson,
Ohio: Lexi-Comp, 2006.
337.
WOLFE, M.M. Overview and comparison of the proton pump inhibitors for the treatment
of acid-related disorders. Waltham, MA: UpToDate, 2010. Disponível em:
< http://www.uptodate.com/contents/
overview-and-comparison-of-the-proton-pump-inhibitors-for-the-treatment-of-acid-related-disorders?source=search_
result&selectedTitle=1%7E150>. Acesso em: 13 fev. 2011.
338.
GILL, S.K. et al. The safety of
proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. American Journal of
Gastroenterology, New
York, v. 104, p. 1541-1545, 2009.
339.
PASTERNAK, B.; HVIID, A. Use of
proton-pump inhibitors in early pregnancy and the risk of birth defects. New England Journal of Medicine, Waltham, v. 363 , n. 22, p. 2114-2123, 2010.
340.
ROMANO, C. et al. Proton pump
inhibitors in pediatrics: Evaluation of efficacy in GERD therapy. Current Clinical Pharmacology, San
Francisco, CA, 2011 Jan 11. Epub ahead of print.
341.
WANNMACHER,
L. Inibidores da bomba de prótons: indicações racionais. Uso Racional de Medicamentos: Temas
Selecionados. Brasília, DF, v. 2, n. 1, dez. 2004. Disponível em:
<http://www. opas.org.br/medicamentos/site/UploadArq/HSE_
URM_IBP_1204.pdf>. Acesso em: 13 fev. 2011.
342.
CHANG, A.B. et al. Gastro-oesophageal
reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database of Systematic Reviews,
Oxford, 2011 Jan 19; 1. CD004823.
343.
VAN PINXTEREN, B. Short-term
treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics
for gastro-oesophageal reflux disease-like symptoms and endoscopy negative
reflux disease. Cochrane Database of Systematic Reviews,
Oxford, 2010 Nov 10;11. CD002095.
344.
CALVET, X. et al. A meta-analysis of
short versus long therapy with a proton pump inhibitor, clarithromycin and
either metronidazole or amoxycillin for treating Helicobacter pylori infection.
Alimentary Pharmacology and
Therapeutics, Oxford, v. 14, n. 5, p. 603-609, 2000.
345.
CHEY, W.D.; WONG, B.C. American
College of Gastroenterology guideline on the management of Helicobacter pylori
infection. American Journal of Gastroenterology, New York, v. 102, p. 1808-1825, 2007.
346.
MALFERTHEINER, P. et al. Current
concepts in the management of Helicobacter pylori infection: the Maastricht III
Consensus Report. Gut, London,
v. 56, p. 772-781, 2007.
347.
GISBERT, J.P.; GONZALEZ, L.; CALVET,
X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine
bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter, Cambridge, v. 10, n. 3, p. 157-171, 2005.
348.
FESTI, D. et al. Body weight,
lifestyle, dietary habits and gastroesophageal reflux disease. World Journal of Gastroenterology, Beijing,
v. 15, n. 14, p. 1690-1701, 2009.
349.
DONNELLAN, C. et al. WITHDRAWN:
Medical treatments for the maintenance therapy of reflux oesophagitis and
endoscopic negative reflux disease. Cochrane
Database of Systematic Reviews, Oxford, 2010 Feb 17; 2. CD003245.
350.
TAHA, A.S, et al. Famotidine for the
prevention of peptic ulcers and oesophagitis in patients taking low-dose
aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled
trial. Lancet, London, v. 374,
n. 9684, p. 119-125, 2009.
351.
LAI, K.C. et al. Lansoprazole for the
prevention of recurrences of ulcer complications from long-term low-dose
aspirin use. New England Journal of
Medicine, Waltham ,v. 346, p. 2033-2038, 2002.
352.
CHAN, F.K. et al. Preventing
recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori
infection who are taking low-dose aspirin or naproxen. New England Journal of Medicine, Waltham ,v. 344, p. 967-973,
2001.
353.
KEYVANI, L. et al. Pre-endoscopic
proton pump inhibitor therapy reduces recurrent adverse gastrointestinal
outcomes in patients with acute non-variceal upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics,
Oxford, v. 24, n. 8, p. 1247-1255, 2006.
354.
KHUROO, M.S. et al. Treatment with
proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a
meta-analysis. Journal of
Gastroenterology and Hepatology, Carlton, v. 20, n. 1, p. 11-25, 2005.
355.
LEONTIADIS, G. I.; SHARMA, V. K.;
HOWDEN, C. W. WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer
bleeding. Cochrane Database of Systematic Reviews, Oxford, 2010 May 12; 5. CD002094.
356.
SREEDHARAN, A. et al. Proton pump
inhibitor treatment initiated prior to endoscopic diagnosis in upper
gastrointestinal bleeding. Cochrane
Database of Systematic Reviews, Oxford, 2010 Jul 7; 7. CD005415.
357.
LEONTIADIS, G.I. et al. Systematic
reviews of the clinical effectiveness and cost-effectiveness of proton pump
inhibitors in acute upper gastrointestinal bleeding. Health Technology Assessment, Winchester, v. 11, n. 51, p.1-164,
2007.
358.
DELANEY B. et al. WITHDRAWN: Initial
management strategies for dyspepsia. Cochrane
Database of Systematic Reviews, Oxford, 2009 Oct 7; 4. CD001961
359.
MOAYYEDI, P. et al. Pharmacological
interventions for non-ulcer dyspepsia. Cochrane
Database of Systematic Reviews, Oxford, 2006 Oct 18; 4. CD001960.
360.
SOLL, A.H. Pharmacology of antiulcer medications. Waltham, MA: UpToDate, 2009. Disponível em:
<http://www.uptodate.com/
contents/pharmacology-of-antiulcer-medications>. Acesso em: 13 fev. 2011.
361.
GISBERT, J.P.; PAJARES, J.M.
Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis.
Digestive and Liver Disease, Roma, v. 36, n. 4, p. 253-259, 2004.
362.
GISBERT, J.P. et al. Pantoprazole
based therapies in Helicobacter pylori eradication: a systematic review and
meta-analysis. European Journal of Gastroenterology
and Hepatology, London, v. 16, n. 1, p. 89-99, 2004.
363.
CHOI, H.S. et al. Double-dose,
new-generation proton pump inhibitors do not improve Helicobacter pylori
eradication rate. Helicobacter,
Cambridge, v. 12, n. 6, p. 638-642, 2007.
364.
WU, I. et al. Rabeprazole-versus
esomeprazole-based eradication regimens for H. pylori infection. Helicobacter, Cambridge, v. 12, n. 6,
p. 633-637, 2007.
365.
WOLFE, M.M.; SACHS, G. Acid
suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal
reflux disease, and stress-related erosive syndrome. Gastroenterology, Philadelphia, v. 118, p. S9- S31, 2000.
366.
KAHRILAS, P.J. Medical management of gastroesophageal reflux
disease in adults. Waltham,
MA: UpToDate, 2010. Disponível em: <www.uptodateonline.com>. Acesso em:
13 fev. 2011.
367.
HO, K.Y. et al. Randomized, parallel,
double-blind comparison of the ulcer-healing effects of ilaprazole and
omeprazole in the treatment of gastric and duodenal ulcers. Journal of Gastroenterology, Tokyo, v.
44, n. 7, p. 697-707, 2009.
368.
MINER JR, P.B. et al. Omeprazole-Mg
20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a
comparison of over-the-counter doses of proton pump inhibitors. Alimentary Pharmacology and Therapeutics,
Oxford, v. 31, n. 8, p. 846-851, 2010.
369.
LODATO, F.et al. Adverse effects of
proton pump inhibitors. Best Practice
and Research: Clinical Gastroenterology, London, v. 24, n. 2, p.
193-201, 2010.
370.
GRAY, S.L. et al. Proton pump
inhibitor use, hip fracture, and change in bone mineral density in
postmenopausal women: results from the Womenʹs Health
Initiative. Archives of Internal
Medicine, Chicago, v. 170, n. 9, p. 765-771, 2010.
371.
LAINE, L.; HENNEKENS. C. Proton pump
inhibitor and clopidogrel interaction: fact or fiction? American Journal of
Gastroenterology, New
York, v. 105, n. 1, p. 34-41, 2010.
372.
SHIN, J.M.; SACHS, G. Pharmacology of
proton pump inhibitors. Current
Gastroenterology Reports, Philadelphia, v. 10, n. 6, p. 528–534, 2008.
373.
GIBBONS, T.E.; GOLD, B.D. The use of
proton pump inhibitors in children: a comprehensive review. Pediatric Drugs, Auckland, v. 5, n. 1, p. 25-40, 2003.
374.
WORLD HEALTH ORGANIZATION. What are the risks of diabetes in children? Disponível em:
<http://www.who.int/features/qa/65/en/index.html>. Acesso em: 15 fev.
2011.
375.
MILLER, J.L.; SILVERSTEIN, J.H. The
treatment of type 2 diabetes mellitus in youth: which therapies? Treatments in Endocrinology, Auckland, v. 5, n. 4, p. 201-210, 2006.
376.
WANNMACHER,
L. Novas insulinas: qual a real vantagem? In: ORGANIZAÇÃO PAN-AMERICANA DA
SAÚDE. Farmacoterapia baseada em
evidência. Brasília, DF, 2005. (Temas selecionados, v. 2, n. 8).
Disponível em: <www.opas.org.br/ medicamentos/temas>. Acesso em: 15 fev.
2011.
377.
JEFFERIES, C.A.; HAMILTON, J.;
DANEMAN, D. Potential adjunctive therapies in adolescents with type 1 diabetes
mellitus. Treatments in Endocrinology, Auckland, v. 3, n. 6, p. 337-343, 2004.
378.
WANNMACHER,
L. Antidiabéticos orais: comparação entre diferentes intervenções. In:
ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE. Farmacoterapia
baseada em evidência. Brasília, DF, 2005. (Temas selecionados, v. 2, n.
11).
379.
BRITISH MEDICAL ASSOCIATION; ROYAL
PHARMACEUTICAL SOCIETY OF GREAT BRITAIN. British National Formulary 60. London: BMJ Group and Pharmaceutical Press, 2010.
380.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais:
Rename 2010. 7 ed. Brasília, DF, 2010.
381.
LASSERSON, D.S. et al. Optimal insulin
regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia, New York, v. 52, n. 10,
p. 1990-2000, 2009.
382.
MISSO, M.L. et al. Continuous
subcutaneous insulin infusion (CSII) versus multiple insulin injections for
type 1 diabetes mellitus. Cochrane
Database of Systematic Reviews, Oxford, n. 1, 2010 Jan 20. CD005103.
383.
DAVIS, S.N. Insulin, oral
hypoglycemic agents, and the pharmacology of endocrine pancreas. In: BRUTON,
L.L.; LAZO, J.S.; PARKER, K.L. (Ed.). Goodman
& Gilman’s: the pharmacological basis of therapeutics. 11. ed. New
York: McGraw-Hill, 2006. p. 1613-1645.
384.
SINGH, S.R. et al. Efficacy and
safety of insulin analogues for the management of diabetes mellitus: a
meta-analysis. CMAJ: Canadian
Medical Association Journal, Ottawa, v. 180, n. 4, p. 385-397, 2009.
385.
PRATOOMSOOT , C. et al. An estimation
of the long-term clinical and economic benefits of insulin lispro in Type 1
diabetes in the UK. Diabetic Medicine,
Chichester, v. 26, n.8, p. 803-814, 2009.
386.
DUCKWORTH, W.; DAVIS, S.N. Comparison
of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a
review of clinical studies. Journal of
Diabetes and its Complications, New York, v. 21, n. 3, p. 196-204, 2007.
387.
MONAMI, M.; MARCHIONNI, N.; MANNUCCI
,E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes,
Obesity & Metabolism, Oxford, v. 11, n. 4, p. 372-378, 2009.
388.
WAUGH, N. et al. Newer agents for
blood glucose control in type 2 diabetes: systematic review and economic
evaluation. Health Technology
Assessment, Rockville, v. 14, n. 36, p. 1-248, 2010.
389.
WARREN, E. et al. Systematic review
and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment,
Rockville, v. 8, n. 45, p. 1-57, 2004.
390.
HORVATH, K. et al. A. Long-acting
insulin analogues versus NPH insulin (human isophane insulin) for type 2
diabetes mellitus. Cochrane Database of
Systematic Reviews, Oxford, n.12, 2010. CD005613.
391.
VARDI, M. et al. Intermediate acting
versus long acting insulin for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews,
Oxford, n. 12, 2010. CD006297.
392.
OROZCO, L.J. et al. Exercise or
exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database of Systematic Reviews,
Oxford, n.12, 2010. CD003054.
393.
CRESPÍ-MONJO,
M. et al. Estudio prospectivo y aleatorizado de intercambio terapéutico de
sulfonilureas en pacientes con diabetes mellitus tipo 2. Farmacia Hospitalaria , Madrid, v. 28,
n. 6, p.426-432, 2004.
394.
GONZÁLEZ-ORTIZ,
M. et al. Efficacy of glimepiride/metformin combination versus
glibenclamide/ metformin in patients with uncontrolled type 2 diabetes
mellitus. Journal of Diabetes and its
Complications, New York, v. 23, n. 6, p. 376-379, 2009.
395.
ALVARSSON, M. et al. Ef fects of
insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes:
a 4-year follow-up. Diabetes, Obesity
& Metabolism, Oxford, v. 10, n. 5, p. 421-429, 2008.
396.
GOTTSCHALK, M. et al. Glimepiride
versus metformin as monotherapy in pediatric patients with type 2 diabetes: a
randomized, single-blind comparative study. Diabetes Care, New York, v. 30, n. 4, p. 790-794, 2007.
397.
SAENZ, A. et al. Metformin
monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, Oxford, n.12, 2010.
CD002966.
398.
SALPETER, S.R. et al. Risk of fatal
and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews,
Oxford, n. 12, 2010. CD002967.
399.
SILVA,
J.C. et al. Metformin compared with glyburide for the management
of gestational diabetes. International
Journal of Gynaecology and Obstetrics, New York, v. 111, n. 1, p. 37-40,
2010.
400.
KANE, M.P.; ABU-BAKER, A.; BUSCH,
R.S. The utility of oral diabetes medications in type 2 diabetes of the young. Current Diabetes Reviews, Saif Zone, v. 1, n. 1, p. 83-92, 2005.
401.
QUINN, S.M. et al. Treatment of
clinical insulin resistance in children: a systematic review. Obesity Reviews, Oxford, v. 11,
402.
n. 10,
p. 722-730, 2010.
403.
ABDELGHAFFAR, S.; ATTIA, A.M.
Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.
Cochrane Database of Systematic Reviews, Oxford, n. 12, 2010. CD006691.
404.
PARK, M.H. et al. Metformin for
obesity in children and adolescents: a systematic review. Diabetes Care, New York, v. 32, n. 9,
p. 1743- 1745, 2009.
405.
WILSON, D.M. et al. Metformin
extended release treatment of adolescent obesity: a 48-week randomized,
double-blind, placebo-controlled trial with 48-week follow-up. Archives of Pediatrics & Adolescent
Medicine, Chicago, v. 164, n. 2, p. 116-123, 2010. Glaser Pediatric
Research Network Obesity Study Group.
406.
WIEGAND, S. et al. Metformin and
placebo therapy both improve weight management and fasting insulin in obese
insulin-resistant adolescents: a prospective, placebo-controlled, randomized
study. European Journal of
Endocrinology, Oslo, v. 63, n. 4, p. 585-592, 2010
407.
CUMMINGS, S.R.; MELTON, L.J.
Epidemiology and outcomes of osteoporotic fractures. Lancet, London, v. 359, n. 9319, p. 1761–1767, May 2002.
408.
FLEURENCE, R.L.; IGLESIAS, C.P.;
JOHNSON, J.M. The cost effectiveness of bisphosphonates for the prevention and
treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics, Auckland, v. 25, n. 11, p. 913-933, 2007.
409.
IGLESIAS, C.P.; MANCA, A.; TORGERSON,
D.J. The health-related quality of life and cost implications of falls in
elderly women. Osteoporosis International, London, v. 20, n. 6, p. 869-878, Jun. 2009.
410.
LIPPUNER, K. et al. Fracture
hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporosis International, London,
2010 Dec 9. Epub ahead of print.
411.
MCCLOSKEY, E. Preventing osteoporotic
fractures in older people. Practitioner, London, v. 255, n. 1736, p. 19-22, 2-3, Jan. 2011.
412.
SIRIS, E.S.; BAIM, S.; NATTIV, A.
Primary care use of FRAX: absolute fracture risk assessment in postmenopausal
women and older men. Postgraduate Medicine, New York, v. 122, n. 1, p. 82-90, Jan. 2010.
413.
FRANCIS, R.M. et al. Calcium and
vitamin D in the prevention of osteoporotic fractures. QJM: monthly journal of the Association of Physicians, [Oxford],
v. 99, n. 6, p. 355-363, Jun. 2006.
414.
MCTIERNAN, A. et al. Low-fat,
increased fruit, vegetable, and grain dietary pattern, fractures, and bone
mineral density: the Women’s Health Initiative Dietary Modification Trial. The American Journal of Clinical Nutrition,
Bethesda, v. 89, n. 6, p. 1864-1876, Apr. 2009.
415.
MOAYYERI, A. The association between
physical activity and osteoporotic fractures: a review of the evidence and
implications for future research. Annals of Epidemiology, New York, n. 18, p. 827-835, Nov. 2008.
416.
BONAIUTI, D. et al. Exercise for
preventing and treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews,
Oxford, n. 2, 2011. Art. No. CD000333.
417.
BOCALINI, D.S. Strength training
preserves the bone mineral density of postmenopausal women without hormone
replacement therapy. Journal of Aging
and Health, [Newbury Park], v. 21, n. 3, p. 519-527, Jun. 2009.
418.
MARTYN, S.T.; JAMES, M.; CARROLL, S.
Meta-analysis of walking for preservation of bone mineral density in
postmenopausal women. Bone, New York, v. 43, n. 3, p. 521-531, Sep. 2008.
419.
QUESADA
GÓMEZ, J.M. et al. Calcium citrate and vitamin D in the
treatment of osteoporosis. Clinical
Drug Investigation, Mairangi Bay, v. 31, n. 5, p. 285-298, 2011.
420.
WANNMACHER,
L. A eficácia de cálcio e vitamina D na prevenção de fraturas ósseas. Farmacoterapia Baseada em Evidência:
Temas selecionados, Brasília, DF, v. 2, n. 10, 2005. Disponível em:
<http://www.opas.org.br/ medicamentos/temas>. Acesso em: 03 jul. 2009.
421.
VESTERGAARD, P.; MOSEKILDE, L.;
LANGDAHL, B. Fracture prevention in postmenopausal women (updated). BMJ Clinical Evidence, London, p. ii:
1109, 2007 Sep 1. Web publication date: 03 Feb 2010 (based on June 2009
search). Acesso em: 01 abr.
2011.
422.
SALOVAARA, K. et al. Effect of
vitamin D(3) and calcium on fracture risk in 65- to 71-year-old women: a
population-based 3-year randomized, controlled trial--the OSTPRE-FPS. Journal of Bone and Mineral Research,
Washington, DC, v. 25, n. 7, p. 1487-1495, Jul. 2010.
423.
LIPS, P. et al. Reducing fracture
risk with calcium and vitamin D. Clinical
Endocrinology, Oxford, v. 73, n. 3, p. 277-285, Sep. 2010.
424.
BRUNNER, R.L. et al. Calcium, vitamin
D supplementation, and physical function in the Women’s Health Initiative. Journal of the American Dietetic Association,
Chicago, v. 108, n. 9, p. 1472-1479, Sep. 2008.
425.
ROUX, C. et al. New insights into the
role of vitamin D and calcium in osteoporosis management: an expert roundtable
discussion. Current Medical Research
and Opinion, Newbury, v. 24, n. 5, p. 1363-1370, May 2008.
426.
AVENELL, A. et al. Vitamin D and
vitamin D analogues for preventing fractures associated with involutional and
post-menopausal osteoporosis. Cochrane
Database of Systematic Reviews, Oxford, n. 2, 2011. Art. No. CD000227.
427.
BERGMAN, G.J. et al. Efficacy of
vitamin D3 supplementation in preventing fractures in elderly women: a
meta-analysis. Current Medical Research and Opinion, Newbury, v. 26, n. 5, p.1193-1201, 2010.
428.
SPANGLER, M. et al. Calcium
supplementation in postmenopausal women to reduce the risk of osteoporotic
fractures. American Journal of
Health-System Pharmacy, Bethesda, v. 68, n. 4, p. 309-318, Feb. 2011.
429.
CONSULTA
remédios. 2011. Disponível em: <http://www.consultaremedios.com.br>.
Acesso em: 2 abr. 2011.
430.
PEARCE, N. et al.; THE ISAAC PHASE
THREE STUDY GROUP. Worldwide trends in the prevalence of asthma symptoms: phase
III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax, London, GB, v. 62, p. 758-766, 2007.
431.
BOUSQUET, J.; KHALTAEV, N. Global surveillance, prevention and control
of chronic respiratory diseases: a comprehensive approach. Geneva: World
Health Organization, 2007. (Global Alliance against Chronic Respiratory
Diseases).
432.
MOORMAN, J. E. et al. Current Asthma
Prevalence: United States, 2006-2008. Morbidity
and Mortality Weekly Report (MMWR), Atlanta, v. 60, n. 01, p. 84-86,
2011.
433.
BRASIL.
Ministério da Saúde. Secretaria Nacional de Ações Básicas. Estatísticas de saúde e mortalidade.
Brasília: Ministério da Saúde, 2005.
434.
SOUZA-MACHADO,
C. et al. Impacto do PROAR (Programa para o controle da asma e da rinite
alérgica na Bahia) sobre a utilização de recursos de saúde, custos e
morbimortalidade por asma em Salvador. Gazeta
Médica da Bahia, Salvador, v. 78, Suplemento 2, p. 59-63, 2008.
435.
GLOBAL FORUM FOR HEALTH RESEARCH. Equitable access: research challenges
for health in developing countries: a report on forum 11, 29 October-2 November
2007, Beijing, People’s Republic of China. Geneva: World Health Organization; 2008.
436.
CRUZ, A. A.; BATEMAN, E. D.;
BOUSQUET, J. The social determinants of asthma. Eur. Respir. J., [S.l.], v. 32, n. 2, p. 239-242, 2010.
437.
BARRETO,
M. L. et al. Ecological study of socio-economic indicators and
prevalence of asthma in schoolchildren in urban Brazil. BMC Public Health, [S.l.], v. 7, p. 205, 2007.
438.
MORGAN, W. J. et al. Outcome of
asthma and wheezing in the first 6 years of life: follow-up through
adolescence. Am. J. Respir. Crit. Care
Med., [S.l.], v. 172, n. 10, p. 1253-1258, 2005.
439.
LIM, R. H.; KOBZIK, L.; DAHL, M. Risk
for asthma in offspring of asthmatic mothers versus fathers: a meta-analysis. PLoS One, v. 5, n. 4, p. e10134, 2010.
440.
HASELKORN, T. et al. Asthma control
and activity limitations: insights from the Real-world Evaluation of Asthma
Control and Treatment (REACT) study. Am.
J. Respir. Crit. Care Med., [S.l.], v. 104, p. 417-471, 2010.
441.
GILSENAN, A. W. et al. Status of
asthma control in pediatric primary care: results from the pediatric Asthma
Control Characteristics and Prevalence Survey Study (ACCESS). J. Pediatr., Saint Louis, v. 157, n.
2, p. 276-281, 2010.
442.
STANFORD, R. H. et al. Predictors of
uncontrolled asthma in adult and pediatric patients: analysis of the Asthma
Control Characteristics and Prevalence Survey Studies (ACCESS). J. Asthma., [S.l.], v. 47, p. 257-262,
2010.
443.
NATIONAL INTITUTES OF HEALTH.
National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert
panel report 3. Washington,
DC: Department of Health and Human Services, 2007.
444.
ROY, A.; DOWNES, M. J.; WISNIVESKY,
J. P. Comprehensive environmental management of asthma and pediatric preventive
care. Pediatr. Allergy Immunol., [S.l.], v. 22, n. 3, p. 277-282, 2011.
445.
BURGESS, J. A. et al. Factors
influencing asthma remission: a longitudinal study from childhood to middle
age. Thorax, London, GB, Mar.
30, 2011. [Epub ahead of print].
446.
AMARAL,
R. Antiasmáticos. In: FUCHS, F. D.; WANNMACHER, L. (Eds.). Farmacologia Clínica: fundamentos da
terapêutica racional. 4. ed. Rio de Janeiro: gen/ Guanabara Koogan, 2010. p.
947-965.
447.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais:
Rename 2010. 7. ed. Brasília: Ministério da Saúde, 2010. 250 p.
448.
HANANIA, N. A.; DICKEY, B. F.; BOND,
R. A. Clinical implications of the intrinsic efficacy of beta-adrenoceptor
drugs in asthma: full, partial and inverse agonism. Curr. Opin. Pulm. Med., [S.l.], v. 16, n. 1, p. 1-5, 2010.
449.
WELSH, E. J.; CATES, C. J. Formoterol
versus short-acting beta-agonists as relief medication for adults and children
with asthma. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 03, 2011. Art. No. CD008418.
450.
CAMARGO Jr., C. A.; RACHELEFSKY, G.;
SCHATZ, M. Summary of the National Asthma Education and Prevention Program
Expert Panel report 3: guidelines for the management of asthma exacerbations. Proc. Am. Thor. Soc., [S.l.], v. 6, p. 357-366, 2009.
451.
RODRIGO, G. J.; CASTRO-RODRIGUEZ, J.
A. Anticholinergics in the treatment of children and adults with acute asthma:
a systematic review with meta-analysis. Thorax, London, GB, v. 60, p. 740-746, 2005.
452.
PLOTNICK, L.; DUCHARME, F. Combined
inhaled anticholinergics and beta2-agonists for initial treatment of acute
asthma in children. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 03, 2011. Art. No. CD000060.
453.
CYDULKA, R. K.; EMERMAN, C. L.; MUNI,
A. Levalbuterol versus levalbuterol plus ipratropium in the treatment of severe
acute asthma. J. Asthma., [S.l.], v. 47, n. 10, p. 1094-1100, 2010.
454.
SUISSA, S.; ERNST, P. Inhaled
corticosteroids: impact on asthma morbidity and mortality. J. Allergy Clin. Immunol., Saint Louis, v. 107, p. 937-944, 2001.
455.
MAIN, C. et al. Systematic review and
economic analysis of the comparative effectiveness of different inhaled
corticosteroids and their usage with long-acting beta2 agonists for the
treatment of chronic asthma in children under the age of 12 years. Health Technol. Assess, [S.l.], v. 12,
n. 20, p. 1-174, 2008.
456.
POWELL, H,; GIBSON, P. G. High dose
versus low dose inhaled corticosteroid as initial starting dose for asthma in
adults and children. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 3, 2011. Art. No. CD004109.
457.
ZHANG, L. et al. Dose response of
inhaled corticosteroids in children with persistent asthma: a systematic
review. Pediatrics, New York, v.
127, n. 1, p. 129-138, 2011.
458.
QUON, B. S. et al. Increased versus
stable doses of inhaled corticosteroids for exacerbations of chronic asthma in
adults and children. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 03, 2011. Art. No. CD007524.
459.
ADAMS, N. P.; BESTALL, J. C.; JONES,
P. Beclomethasone at different doses for chronic asthma. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 03,2011. Art. No. CD002879.
460.
MIROSHNIK, I. et al. Outcomes after
periodic use of inhaled corticosteroids in children. J. Asthma, [S.l.], v. 46, n. 5, p. 517-522, 2009.
461.
MARTINEZ, F. D. et al. Use of
beclomethasone dipropionate as rescue treatment for children with mild
persistent asthma (TREXA): a randomised, double-blind, placebo-controlled
trial. Lancet, London, v. 377, n.
9766, p. 650-657, 2011.
462.
PAPI, A. et al; BEST STUDY GROUP.
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.
N. Engl. J. Med.,
[S.l.], v. 356, n. 20, p. 2040-2052, 2007.
463.
BOUSHEY, H. A. et al.; NATIONAL
HEART, LUNG, AND BLOOD INSTITUTE’S ASTHMA CLINICAL RESEARCH NETWORK. Daily
versus as-needed corticosteroids for mild persistent asthma. N. Engl. J. Med., [S.l.], v. 352, n.
15, p. 1519-1528, 2005.
464.
SELF, T. H. et al. Inhaled
corticosteroids should be initiated before discharge from the emergency
department in patients with persistent asthma. J. Asthma, [S.l.], v. 46, n. 10, p. 974-979, 2009.
465.
CASTRO-RODRIGUEZ, J. A.; RODRIGO, G.
J. The role of inhaled corticosteroids and montelukast in children with
mild-moderate asthma: results of a systematic review with meta-analysis. Arch. Dis. Child, London, v. 95, n. 5, p. 365-370, 2010.
466.
TASCHE, M. J. et al. Inhaled disodium
cromoglycate (DSCG) as maintenance therapy in children with asthma: a
systematic review. Thorax,
London, GB, v. 55, p. 913-920, 2000.
467.
THE CHILDHOOD ASTHMA MANAGEMENT
PROGRAM RESEARCH GROUP. Long-term effects of budesonide or nedocromil in
children with asthma. N. Engl. J. Med., [S.l.], v. 343, p. 1054-1063, 2000.
468.
UIJEN, J. H. J. M. et al. Inhaled
sodium cromoglycate for asthma in children. Cochrane Database of Systematic
Reviews. In: The Cochrane Library,
n. 3, 2011. Art.
No. CD002173.
469.
RANDELL, T. L. et al. Safety of the
newer inhaled corticosteroids in childhood asthma. Paediatr. Drugs, [S.l.], v. 5, p. 481-504, 2003.
470.
SHAREK, P. J.; BERGMAN, D.; DUCHARME,
F. Beclomethasone for asthma in children: effects on linear growth. Cochrane
Database of Systematic Reviews. In: The
Cochrane Library, n. 03, 2011. Art. No. CD001282.
471.
O’BYRNE, P. M. et al. Risks of
pneumonia in patients with asthma taking inhaled corticosteroids. Am. J. Respir. Crit. Care Med.,
[S.l.], v. 183, n. 5, p. 589-595, 2011.
472.
WEATHERALL, M. et al. Dose-response
relationship of inhaled corticosteroids and cataracts: a systematic review and
meta-analysis. Respirology,
[S.l.], v. 14, n. 7, p. 983-990, 2009.
473.
BALTER, M. S. et al. Management of
asthma in adults. CMAJ, [S.l.],
v. 181, n. 12, p. 915-922, 2009.
474.
STOCKL, K. M. et al. Use of
controller medications in patients initiated on a long-acting beta2-adrenergic
agonist before and after safety alerts. Am.
J. Health Syst. Pharm., [S.l.], v. 65, n. 16, p. 1533-1538, 2008.
475.
SAZONOV-KOCEVAR,
V. et al. Asthma and allergy medication use and costs among
pediatric primary care patients on asthma controller therapy. Pediatr. Allergy Immunol., [S.l.], v.
17, n. 8, p. 620-628, 2006.
476.
GREENSTONE, I. et al. Addition of
long-acting beta2-agonists to inhaled steroids as first line therapy for
persistent asthma in steroid-naive adults and children. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, n. 03, 2011. Art. No. CD005307.
477.
DUCHARME, F. M. et al. Addition of
long-acting beta2-agonists to inhaled steroids versus higher dose inhaled
steroids in adults and children with persistent asthma. Cochrane Database of Systematic
Reviews. In: The Cochrane Library,
n. 03, 2011. Art.
No. CD005533.
478.
DUCHARME, F. M. et al. Addition of
long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled
corticosteroids for chronic asthma in adults and children. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, n. 03, 2011. Art. No. CD005535.
479.
CATES, C. J.; LASSERSON, T. J.
Combination formoterol and budesonide as maintenance and reliever therapy
versus inhaled steroid maintenance for chronic asthma in adults and children.
Cochrane Database of Systematic Reviews. In: The Cochrane Library, n. 03, 2011. Art. No. CD007313.
480.
NELSON, H. S. et al. The Salmeterol
Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for
asthma or usual pharmacotherapy plus salmeterol. Chest, Chicago, v. 129, p. 15-26, 2006.
481.
BATEMAN, E. et al. Meta-analisys:
effects of adding salmeterol to inhaled corticosteroids on serious
asthma-related events. Ann. Intern. Med., [S.l.], v. 149, p. 33-42, 2008.
482.
GUO, J. J. et al. Risk of serious
asthma exacerbations associated with long-acting beta agonists among patients
with asthma: a retrospective cohort study. Ann. Allergy Asthma Immunol., v. 106, n. 3, p. 214-222, 2011.
483.
LIAO, M. M. et al. Salmeterol use and
risk of hospitalization among emergency department patients with acute asthma. Ann. Allergy Asthma Immunol., [S.l.],
v. 104, n. 6, p. 478-484, 2010.
484.
PRICE, J. F. et al. Safety of
formoterol in children and adolescents: experience from asthma clinical trials.
Arch. Dis. Child., London, GB,
v. 95, n. 12, p. 1047-1053, 2010.
485.
WEATHERALL, M. et al. Meta-analysis
of the risk of mortality with salmeterol and the effect of concomitant inhaled
corticosteroid therapy. Thorax,
London, GB, v. 65, n. 1, p. 39-43, 2010.
486.
CATES, C. J.; LASSERSON, T. J.
Regular treatment with formoterol versus regular treatment with salmeterol for
chronic asthma: serious adverse events. Cochrane Database of Systematic
Reviews. In: The Cochrane Library,
n. 03, 2011. Art.
No. CD007695.
487.
CATES, C. J.; LASSERSON, T. J.
Regular treatment with formoterol and an inhaled corticosteroid versus regular
treatment with salmeterol and an inhaled corticosteroid for chronic asthma:
serious adverse events. Cochrane Database of Systematic Reviews. In: The Cochrane Library, n. 03, 2011. Art. No. CD007694
488.
GUS,
M.; FUCHS, F. D. Antitrombóticos. In: FUCHS, F.D.; WANNMACHER, L. (
Ed.) Farmacologia clínica:
fundamentos da terapêutica racional. 4. ed. Rio de Janeiro: Guanabara Koogan,
2010. p. 891-910.
489.
BANE, M. C.; WYSOKINSKI, R. D.
Pathophysiology of arterial thrombosis. In: MURPHY, J. D.; LLOYD, M. A. (Org). Mayo Clinic Cardiology. 3. ed. Florida: Taylor & Francis Group, 2007. p. 625-634.
490.
SCURR, J.H. et al. Frequency and
prevention of symptomless deep-vein thrombosis in long-haul flights: a
randomised trial. Lancet,
London, v. 357, n. 9267, p. 1485-1489, May 2001.
491.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação nacional de medicamentos essenciais:
Rename 2010. 7. ed. Brasília, DF, 2010. 250 p.
492.
ANTITHROMBOTIC TRIALISTS’ (ATT)
COLLABORATION. Aspirin in the primary and secondary prevention of vascular
disease: collaborative meta-analysis of individual participant data from
randomised trials. Lancet, London, v. 373, n. 9678, p. 1849-1860, May 2009.
493.
POLANCZYK,
C. A.; FURTADO, M. V.; FUCHS, F. D. Fármacos usados em cardiopatia isquêmica.
In: FUCHS, F. D.; WANNMACHER, L. (Ed.). Farmacologia
clínica: fundamentos da terapêutica racional. 4. ed. Rio de Janeiro:
Guanabara Koogan, 2010. p. 818-842.
494.
STAVRAKIS, S. et al. Low-dose aspirin
for primary prevention of cardiovascular events in patients with diabetes: a
meta-analysis. The American Journal of
the Medical Sciences, Philadelphia, v. 341, n. 1, p. 1-9, Jan. 2011.
495.
OWEN, A. Antithrombotic treatment for
the primary prevention of stroke in patients with non valvular atrial
fibrillation: a reappraisal of the evidence and network meta-analysis. International Journal of Cardiology, Amsterdam, v. 142, n. 3, p. 218-223, Jan. 2010.
496.
GOLDSTEIN, L. B. et al. American
Heart Association; American Stroke Association Stroke Council. Primary
prevention of ischemic stroke: a guideline from the American Heart Association/
American Stroke Association Stroke Council: cosponsored by the Atherosclerotic
Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular
Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and
Metabolism Council; and the Quality of Care and Outcomes Research
Interdisciplinary Working Group. Circulation, Dallas, v. 113, n. 24, p. e873-923, Jun. 2006.
497.
BOZIC, K.J. et al. Does aspirin have
a role in venous thromboembolism prophylaxis in total knee arthroplasty
patients? The Journal of Arthroplasty,
New York, v. 25, n. 7, p. 1053-1060, Aug. 2010.
498.
LIÈVRE, M.; CUCHERAT, M. Aspirin in
the secondary prevention of cardiovascular disease: an update of the APTC
meta-analysis. Fundamental & Clinical Pharmacology, Paris, v. 24, n. 3, p. 385-391, Jun. 2010.
499.
ANTITHROMBOTIC TRIALISTS’
COLLABORATION. Collaborative meta-analysis of randomised trials of antiplatelet
therapy for prevention of death, myocardial infarction, and stroke in high risk
patients. BMJ, London, v. 324, n. 7330, p. 71-86, Jan. 2002.
500.
SUDLOW, C. L. M. et al.
Thienopyridine derivatives versus aspirin for preventing stroke and other
serious vascular events in high vascular risk patient. Cochrane Database Syst Rev, Oxford, Issue 04, Oct. 2009. Art. No.
CD001246.
501.
YUSUF, S. et al. Effects of
clopidogrel in addition to aspirin in patients with acute coronary syndromes
without ST-segment elevation. The New
England Journal of Medicine, Boston, v. 345, n. 7, p. 494-502, Aug.
2001.
502.
MEHTA, S. R. et al. Effects of
pretreatment with clopidogrel and aspirin followed by long-term therapy in
patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, London, v. 358, n. 9281, p.
527-533, Aug. 2001.
503.
SQUIZZATO, A. et al. Clopidogrel plus
aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev, Oxford,
Issue 01, Jan. 2011 CD005158.
504.
DIENER, H. C. et al Efects of aspirin
plus extended-release dipyridamole versus clopidogrel and telmisartan on
disability and cognitive function after recurrent stroke in patients with
ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second
Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology, London, v. 7, n. 10, p. 875-884, Oct. 2008.
505.
DIENER, H. C. et al. Aspirin and
clopidogrel compared with clopidogrel alone after recent ischaemic stroke or
transient ischaemic attack in high-risk patients (MATCH): randomised,
double-blind, placebo-controlled trial. Lancet,
London, v. 364, n. 9431, p. 331-337, 2004.
506.
KAMAL, A.K. et al. Cilostazol versus
aspirin for se condary prevention of vascular events after stroke of arterial
origin. Cochrane Database Syst Rev,
Oxford, Issue 01, Jan. 2011. CD008076.
507.
JENNINGS, D. L.; KALUS, J. S.
Addition of cilostazol to aspirin and a thienopyridine for prevention of
restenosis after coronary artery stenting: a meta-analysis. Journal of Clinical Pharmacology, Stamford, v. 50, n. 4, p. 415-421, Apr. 2010.
508.
ZHAO, H. J. et al. Triple therapy”
rather than “triple threat”: a meta-analysis of the two antithrombotic regimens
after stent implantation in patients receiving long-term oral anticoagulant
treatment. Chest, Northbrook, v. 139, n. 2, p. 260- 270, Feb. 2011.
509.
VERHAGEN, A. P. et al. Treatment of
tension type headache: paracetamol and NSAIDs work: a systematic review. Ned. Tijdschr. Geneeskd., [S. l.], v.
154, A1924, 2010.
510.
FERREIRA,
M. B. C. Princípios gerais no tratamento de dor. In: FUCHS, F. D.; WANNMACHER, L.
(Eds.) Farmacologia Clínica:
fundamentos da terapêutica racional. 4. ed. Rio de Janeiro: GEN/Guanabara
Koogan, 2010. p. 214-230.
511.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais:
Rename 2010. 7. ed. Brasília: Ministério da Saúde, 2010. 250 p.
512.
ONG, C. K. S. et al. An
evidence-based update on nonsteroidal anti-inflammatory drugs. Clin. Med. Res., [S. l.], v. 5, n. 1, p. 19-34, 2007.
513.
SACHS, C. J. Oral analgesics for
acute nonspecific pain. Am. Fam. Phys.,
[S. l.], v. 71, p. 913-918, 2005.
514.
TOMS, L. et al. Single dose oral
paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database
of Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD004602.
515.
WEIL, K. et al. Paracetamol for pain
relief after surgical removal of lower wisdom teeth. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD004487.
516.
ROELOFS, P. D. D. M. et al.
Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD000396.
517.
BUCKLEY, N.; EDDLESTON, M.
Paracetamol (acetaminophen) poisoning. In.: BMJ Clinical Evidence, 2010. Web publication date: 04 Dec 2007
(based on March 2007 search).
518.
MATTIA, C.; COLUZZI, F. What
anesthesiologists should know about paracetamol (acetaminophen). Minerva Anestesiol, [S. l.], v. 75, n. 11, p. 644-653, 2009.
519.
OSCIER, C. D.; MILNER, Q. J. W.
Peri-operative use of paracetamol. Anaesthesia, [S. l.], v. 64, p. 64-72, 2009.
520.
WANNMACHER,
L. Paracetamol versus dipirona: como mensurar o risco? In: Opas. Uso racional de medicamentos: temas
selecionados, Brasília, v. 2, n. 5, abril 2005.
521.
DERRY, C. et al. Single dose oral
ibuprofen for acute postoperative pain in adults. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD001548.
522.
WAHBA, H. The antipyretic effect of
ibuprofen and acetaminophen in children. Pharmacotherapy, [S. l.], v. 24, p. 280-284, 2004.
523.
EDWARDS, J. et al. Single dose oral
aspirin for acute pain. Cochrane Database of Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD002067.
524.
EDWARDS, J. et al. Single dose
dipyrone for acute postoperative pain. Cochrane Database of Systematic Reviews.
In: The Cochrane Library, Issue
10, 2010. Art.
No. CD003227.
525.
RAMACCIOTTI, A. S.; SOARES, B.;
ATALLAH, A. N. Dipyrone for acute primary headaches. Cochrane Database of
Systematic Reviews. In: The Cochrane
Library, Issue 10, 2010. Art. No. CD004842.
526.
EDWARDS, J. et al. Single dose
dipyrone for acute renal colic pain. Cochrane Database of Systematic Reviews.
In: The Cochrane Library, Issue
10, 2010. Art.
No. CD003867.
527.
HAMERSCHLAK, N.; CAVALCANTI, A.B.
Neutropenia, agranulocytosis and dipyrone. Med. J., São Paulo, v. 123, n. 5, p.247-249, 2005.
528.
IBANEZ, L. et al. Agranulocytosis
associated with dipyrone (metamizol). Eur.
J. Clin. Pharmacol., [S. l.], v. 60, n. 11, p. 821-829, 2005.
529.
IBANEZ, L. et al. Population-based
drug-induced agranulocytosis. Arch.
Intern. Med., [S. l.], v. 165, n. 8, p. 869-874, 2005.
530.
SCHONHOFER, P. S. Dipyrone
(Metamizol): Restored to Good Reputate? Internistiche Praxis, [S. l.], v. 39, p. 184-185, 1999. Disponível em:
<http:// www. sobravime.org.br/disc_dipirona.html>
531.
SCHÜLER-FACCINI, L. et al. Dipyrone
use during pregnancy and adverse perinatal events. Arch. Gynecol. Obstet., [S. l.], v. 279, n. 3, p. 293-297, 2009.
532.
FERREIRA,
M. B. C. Analgésicos não opioides. In: FUCHS, F. D.; WANNMACHER, L.
(Eds.) Farmacologia Clínica:
fundamentos da terapêutica racional. 4. ed. Rio de Janeiro: GEN/Guanabara
Koogan, 2010. p. 342-378.
533.
MCQUAY, H. J.; MOORE, R. A.
Dose-response in direct comparisons of different doses of aspirin, ibuprofen
and paracetamol (acetaminophen) in analgesic studies. Br. J. Clin. Pharmacol., [S. l.], v. 63, n. 3, p. 271-278, 2007.
534.
MELLO,
E. D. de. Prescrição de medicamentos em pediatria. In: FUCHS,
F. D.; WANNMACHER, L. (Eds.) Farmacologia clínica: fundamentos da terapêutica racional. 4. ed. Rio de Janeiro:
GEN/ Guanabara Koogan, 2010. p. 1160-1168.
535.
GILARDÓN,
E. O. A. La fiebre es solo hipertermia? Boletín
PROAPS – Remediar, [S. l.], v. 2, n. 12, 2004. Disponível em:
<www.femeba.org.ar/ fundacion>,. Acesso em:24 nov. 2010.
536.
ANTIPYRETIC drugs for children. BMJ, [S. l.], v. 333, p. 3-5, 2006.
537.
MEREMIKWU, M.; OYO-ITA, A.
Paracetamol versus placebo or physical methods for treating fever in children.
Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 10, 2010. Art. No. CD003676.
538.
ALVES, J. G.; ALMEIDA, N. D.;
ALMEIDA, C. D. Tepid sponging plus dipyrone versus dipyrone alone for reducing
body temperature in febrile children. Med. J., São Paulo, v. 126, n. 2, p. 107-111, 2008.
539.
WANNMACHER,
L.; FERREIRA, M. B. C. Febre: mitos que determinam condutas. In: Farmacoterapia baseada em evidências:
temas selecionados, Brasília, v.1, n. 9, ago. 2004. Disponível em:
<www.opas.org.br/ medicamentos/urm e www.saude.gov.br/sctie>. Acesso em:
24 nov. 2010.
540.
BURKE, A.; SMYTH, E. M.; FITZGERALD,
G. A. Analgesic-antipyretic agents; pharmacotherapy of gout. In: BRUNTON, L.
L.; LAZO, J. S.; PARKER, K. L. (Eds.). Goodman
& Gilman´s the pharmacological basis of therapeutics. 11. ed. New
York: McGraw-Hill, 2006. p. 671-715.
541.
PIERCE, C. A.; VOSS, B. Efficacy and
safety of ibuprofen and acetaminophen in children and adults: a meta-analysis
and qualitative review. Ann. Pharmacother, [S. l.], v. 44. n. 3, p. 489-506, 2010.
542.
SOUTHEY, E. R.; SOARES-WEISER, K.;
KLEIJNEN, J. Systematic review and meta-analysis of the clinical safety and
tolerability of ibuprofen compared with paracetamol in paediatric pain and
fever. Curr. Med. Res. Opin., [S. l.], v. 25, n. 9,
p. 2207-2222, 2009.
543.
KOKKI, H.; KOKKI, M. Ketoprofen
versus paracetamol (acetaminophen) or ibuprofen in the management of fever:
results of two randomized, double-blind, double-dummy, parallel-group,
repeated-dose, multicentre, phase III studies in children. Clin. Drug Investig, [S. l.], v. 30, n. 6, p. 375-386, 2010.
544.
WONG, A. et al. Fever Pediatric Study
Group. Antipyretic effects of dipyrone versus ibuprofen versus acetaminophen in
children: results of a multinational, randomized, modified double-blind study. Clin. Pediatr., [S.l.], v. 40, p. 313-324, 2001.
545.
GOZZOLI, V. et al. Randomized trial
of the effect of antipyresis by metamizol, propacetamol or external cooling on
metabolism, hemodynamics and inflammatory response. Intensive Care Med., [S. l.], v. 30, p. 401-407, 2004.
546.
DIAZ-QUIJANO,
F. A.; VILLAR-CENTENO, L. A.; MARTÍNEZ-VEJA, R. A. Effecto de la administración
temprana de dipirona sobre la gravedad del dengue en una cohorte prospectiva.
Enferm. Infec. Microbiol. Clin.,
[S. l.], v. 23, n. 10, p. 593-597, 2005.
547.
MAYORAL, C. E. et al. Alternating
antipyretics: is this an alternative? Pediatrics,
[S. l.], v. 105, p. 1009-1012, 2000.
548.
KRAMER, L. C. et al. Alternating
antipyretics: antipyretic efficacy of acetaminophen versus acetaminophen
alternated with ibuprofen in children. Clin.
Pediatr., [S. l.], v. 47, n. 9, p. 907-911, 2008.
549.
HAY, A. D. et al. Paracetamol and
ibuprofen for the treatment of fever in children: the PITCH randomised
controlled trial. Health Technol.
Assess., [S. l.], v. 13, n. 27, p. 1-163, 2009.
550.
HOLLINGHURST, S. et al. Paracetamol
plus ibuprofen for the treatment of fever in children (PITCH): economic
evaluation of a randomised controlled trial. BMJ, [S. l.], v. 337, p. a1490, 2008.
551.
HEMAL, A.; KALRA, B. P.; GUPTA, V.
Febrile seizures. J. Indian. Med.
Assoc., [S. l.], v. 108, n. 1, p. 36-38, 2010.
552.
LUX, A. L. Treatment of febrile
seizures: historical perspective, current opinions, and potential future
directions. Brain Dev., [S. l.], v. 32, n. 1, p. 42-50, 2010.
553.
STRENGELL, T. et al. Antipyretic
agents for preventing recurrences of febrile seizures: randomized controlled
trial. Arch. Pediatr. Adolesc. Med.,
[S. l.], v. 163, n. 9, p. 799-804, 2009
554.
BENAZZI, F. Classifying mood
disorders by age-at-onset instead of polarity. Prog. Neuropsychopharmacol Biol. Psychiatry, [S. l.], v. 33, p.
86–93, 2009.
555.
ROY-BYRNE, P. P. et al. Low
socioeconomic status and mental health care use among respondents with anxiety
and depression in the NCS-R. Psychiatr.
Serv., [S. l.], v. 60, p. 1190– 1197, 2009.
556.
SEEDAT, S. et al. Cross-national
associations between gender and mental disorders in the World Health Organization
World Mental Health Surveys. Arch Gen
Psychiatry, [S. l.], v. 66, p. 785–795, 2009.
557.
NOCK, M. K. et al. Cross-national
analysis of the associations among mental disorders and suicidal behavior:
findings from the WHO World Mental Health Surveys. PLOS. Med., [S. l.], v. 6, p. e1000123, 2009.
558.
PAYNE, N. A.; PRUDIC, J.
Electroconvulsive therapy: part II: a biopsychosocial perspective. J. Psychiatr. Pract., [S. l.], v. 15, p. 369–390, 2009.
559.
BARBUI, C. et al. Depression in
adults: drug and physical treatments. In.: BMJ Clinical Evidence 2010. Web publication date: 15 Jun 2007
(based on April 2006 search).
560.
MEAD, G. E. et al. Exercise for
depression. Cochrane Database of Systematic Reviews. In: The Cochrane
Library, n. 10, 2010. Art. No. CD004366.
561.
BUTLER, R. et al. Depression in
adults: psychological treatments and care pathways. BMJ Clinical Evidence 2009. Web publication date: 15 Aug 2007
(based on April 2006 search).
562.
GARBER, J. et al. Prevention of
Depression in At-Risk Adolescents. A Randomized Controlled Trial. JAMA, [S. l.], v. 301, n. 2215-2224,
2009.
563.
CUIJPERS, P. et al. Psychological
treatment of depression in primary care: a meta-analysis. Br. J. Gen. Pract., [S. l.], v. 59, n.
559, p. e51–60, 2009.
564.
SARRIS, J.; KAVANAGH, D. J. Kava and
St. John’s wort: current evidence for use in mood and anxiety disorders. J. Altern. Complement. Med., [S. l.], v. 15, p. 827–836, 2009.
565.
LINDE, K.; BERNER, M. M.; KRISTON, L.
St John’s wort for major depression. Cochrane Database of Systematic Reviews.
In: The Cochrane Library, n. 10,
2010. Art. No. CD000448.
566.
RAHIMI, R.; NIKFAR, S.; ABDOLLAHI, M.
Efficacy and tolerability of hypericum perforatum in major depressive disorder
in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog. Neuropsychopharmacol Biol.
Psychiatry, [S.
l.], v. 33, n. 1, p. 118-127, 2009.
567.
HOU, W. H. et al. Treatment effects
of massage therapy in depressed people: a meta-analysis. J. Clin. Psychiatry, [S. l.], v. 71,
n. 7, p. 894–901, 2010.
568.
WANNMACHER,
L. Antidepressivos e lítio. In: FUCHS, F. D.; WANNMACHER, L. Farmacologia clínica: fundamentos da
terapêutica racional. 4. ed. Rio de Janeiro: GEN/Guanabara Koogan, 2010. p.
741–757.
569.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais:
Rename 2010. 7. ed. Brasília: Ministério da Saúde. 2010. 250 p.
570.
TOHEN, M. et al.
Olanzapine/fluoxetine combination in patients with treatment-resistant
depression: rapid onset of therapeutic response and its predictive value for
subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry, [S. l.], v. 71,
n. 4, p. 451–462, 2010.
571.
ARROLL, B. et al. Antidepressants
versus placebo for depression in primary care. Cochrane Database of Systematic
Reviews. In: The Cochrane Library,
n. 10, 2010. Art.
No. CD007954.
572.
GUAIANA, G.; BARBUI, C.; HOTOPF, M.
Amitriptyline for depression. Cochrane Database of Systematic Reviews. In: The Cochrane Library,
n. 10, 2010. Art. No. CD004186.
573.
CIPRIANI, A. et al. Fluoxetine versus
other types of pharmacotherapy for depression. Cochrane Database of Systematic
Reviews. In: The Cochrane Library, n.
10, 2010. Art.
No. CD004185.
574.
STONE, M. et al. Risk of suicidality
in clinical trials of antidepressants in adults: analysis of proprietary data
submitted to US Food and Drug Administration. BMJ, [S. l.], v. 339, p. b2880, 2009
575.
HAZELL, P. Depression in children and
adolescents. In: BMJ Clinical Evidence
2010. Web publication date: 7 Jan 2009 (based on April 2008 search).
576.
MAYOR, S. Psychological therapy must
accompany antidepressants in young people. BMJ, [S. l.], v. 331, p. 714, 2005.
577.
BRIDGE, J. A. et al. Clinical
response and risk for reported suicidal ideation and suicide attempts in
pediatric antidepressant treatment: a meta-analysis of randomized controlled
trials. JAMA, [S.
l.], v. 297, p. 1683–1696, 2007.
578.
HETRICK, S. et al. Selective
serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and
adolescents. Cochrane Database of Systematic Reviews. In: The Cochrane Library, n. 10, 2010. Art. No. CD004851.
579.
CRAIG, M.; HOWARD, L. Postnatal
depression. In: BMJ Clinical Evidence
2009. Web publication date: 26 Jan 2009 (based on May 2008 search).
580.
WANNMACHER,
L. Depressão perinatal. Farmacoterapia Baseada em Evidência. Temas selecionados, Brasília, OPAS,
v.4, n. 11, 2007. Disponível em: <http://www.opas.org.br/medicamentos/
temas_documentos>. Acesso em: 8 dez. 2010.
581.
MORRELL, C. J. et al. Clinical effectiveness
of health visitor training in psychologically informed approaches for
depression in postnatal women: pragmatic cluster randomised trial in primary
care. BMJ, [S. l.], v. 338,
p. a 3045, 2009.
582.
BARCELOS-FERREIRA,
R. et al. Depressive morbidity and gender in community-dwelling
Brazilian elderly: systematic review and meta-analysis. Int. Psychogeriatr.,
[S. l.], v. 22, n. 5, p. 712–726, 2010.
583.
HUANG, C. Q. et al. Chronic diseases
and risk for depression in old age: a meta-
584.
analysis of published literature. Ageing Res. Rev., [S. l.], v. 9, n. 2, p. 131–141, 2010.
585.
CHANG-QUAN, H. et al. Health status
and risk for depression among the elderly: a meta-analysis of published
literature. Age Ageing, [S. l.], v. 39, n. 1, p. 23–30, 2010.
586.
HATTORI, H. Depression in the
elderly. Nippon Ronen Igakkai Zasshi,
[S. l.], v. 45, p. 451–461, 2008
587.
PERPÉTUO,
I.H.O.; WONG, L.L.R. Desigualdade socioeconômica na utilização de métodos
anticoncepcionais no Brasil: uma análise comparativa com base nas PNDS 1996 e
2006. In: BRASIL. Ministério da Saúde. Pesquisa
Nacional de Demografia e Saúde da Criança e da Mulher - PNDS 2006:
dimensões do processo reprodutivo e da saúde da criança. Brasília, DF:
Ministério da Saúde, 2009. p. 87-104. Disponível em: <http://
bvsms.saude.gov.br/bvs/publicacoes/pnds_ crianca_mulher.pdf>. Acesso em: 10
out. 2010.
588.
BRASIL.
Ministério da Saúde. Secretaria de Atenção à Saúde. Área Técnica de Saúde da
Mulher. Direitos sexuais e direitos
reprodutivos: uma prioridade do governo. Brasília, DF, 2005. 24 p.
589.
BRASIL.
Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação nacional de medicamentos essenciais:
Rename 2010. 7 ed. Brasília, DF, 2010. 250 p.
590.
AMY, J-J.; TRIPATHI, V. Contraception
for women: an evidence based overview. BMJ, London, n. 339, p. b2895, 2009.
591.
HEINEMANN, L.A. et al. Use of oral
contraceptives containing gestodene and risk of venous thromboembolism: outlook
10 years after the third-generation “pill scare”. Contraception, Stoneham , v. 81, n. 5, p. 401-407, 2010.
592.
VAN VLIET, H. A.A.M. et al. Biphasic
versus monophasic oral contraceptives for contraception. Cochrane Database of Systematic Reviews,
Oxford, Issue 10, 2010. Art. No. CD002032.
593.
VAN VLIET, H. A.A.M. et al. Biphasic
versus triphasic oral contraceptives for contraception. Cochrane Database of Systematic Reviews, Oxford, Issue 10, 2010.
Art. No. CD003283. 2006,
Issue 3. Art. No. CD003283.
594.
LUBIANCA,
J.N. Anticoncepcionais orais. In: FUCHS F.D.; WANNMACHER, L. (Ed). Farmacologia clínica: fundamentos da terapêutica racional. 4 ed. Rio de Janeiro:
Guanabara Koogan, 2010. p. 1040-1052.
595.
BACHMANN, G; KORNER P. Bleeding
patterns associated with oral contraceptive use: a review of the literature. Contraception, Stoneham, n. 76, p. 182-189, 2007.
596.
FARQUHAR, C.; BROWN, J. Oral
contraceptive pills for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, Oxford, Issue 10, 2010.
Art. No. CD000154.
597.
WONG, C.L. Et al. Oral contraceptive
pill for primary dysmenorrhoea. Cochrane
Database of Systematic Reviews. Oxford, Issue 10, 2010. Art. No.
CD002120.
598.
MAIA, H.J.; CASOY, J.
Non-contraceptive health benefits of oral contraceptives. Eur. J. Contracept. Reprod. Health Care,
New York, v. 13, p.17-24, 2008.
599.
HANNAFORD, P.C. et al. Cancer risk
among users of oral contraceptives: cohort data from the Royal College of
General Practitioner’s oral contraception study. BMJ, London, v. 335, n. 7621, p. 651, 2007.
600.
AROWOJOLU, A.O. et al. Combined oral
contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews. Oxford, Issue 10, 2010.
Art. No. CD004425.
601.
PALOMBO-KINNE, E. et al. Efficacy of
a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg
dienogest for the treatment of papulopustular acne in comparison with placebo
and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception, Stoneham, n. 79, p. 282-289, 2009.
602.
ESCOBAR-MORREALE, H.F. Diagnosis and
management of hirsutism. Ann. N. Y.
Acad. Sci., New York, n. 1205, p. 166-174, 2010.
603.
AMERICAN COLLEGE OF OBSTETRICIANS AND
GYNECOLOGISTS. ACOG Practice Bulletin No. 73: Use of hormonal contraception in
women with coexisting medical conditions. Obstetrics and Gynecology, New York, n. 107, p.1453-1472, 2006.
604.
WORLD HEALTH ORGANIZATION. Medical eligibility criteria for
contraceptive use. 3 ed. Geneva: WHO Reproductive Health and Research, 2004. 154 p.
605.
SEIBERT, C. et al. Prescribing oral
contraceptives for women older than 35 years of age.A nnals of Internal Medicine, Philadelphia, n. 138, p. 54-64,
2003.
606.
VAN HYLCKAMA VLIEG, A. et al. The
venous thrombotic risk of oral contraceptives, effects of oestrogen dose and
progestogen type: results of the MEGA case-control study. BMJ, London, n. 339, p. b2921, 2009.
607.
KEMMEREN, J.M.; ALGRA, A.; GROBBEE,
D.E. Third generation oral contraceptives and risk of venous thrombosis:
meta-analysis. BMJ, London, n. 323, p. 131-134, 2001.
608.
PARSEY, K.S.; PONG, A. An open-label,
multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive
containing drospirenona, a new progestogen. Contraception, Stoneham, n. 61, p. 105-111, 2000.
609.
HUBER J. et al. Efficacy and
tolerability of a monophasic oral contraceptive containing ethinylestradiol and
drosperinone. Eur. J. Contracept.
Reprod. Health Care, New York, n. 5, p. 25-34, 2000.
610.
LUBIANCA, J.N.; FACCIN, C.S.; FUCHS,
F.D. Oral contraceptives: a risk factor for uncontrolled blood pressure among
hypertensive women. Contraception, Stoneham, n. 67, p. 19-24, 2003.
611.
LUBIANCA, J.N. et al. Stopping oral
contraceptives: an effective blood pressure lowering intervention in women with
hypertension. Journal of Human Hypertension, London, n. 19, p. 451- 455, 2005.
612.
MARTINS, S.L.; CURTIS, K.M.; GLASIER,
A.F. Combined hormonal contraception and bone health: a systematic review. Contraception, Stoneham , v. 73, p. 445-469, 2006.
613.
BEKSINSKA, M.E. et al. Bone mineral
density in a cohort of adolescents during use of norethisterone enanthate,
depot-medroxyprogesterone acetate or combined oral contraceptives and after
discontinuation of norethisterone enanthate. Contraception, Stoneham , v. 79, p. 345-349, 2009.
614.
BERENSON, A.B. et al. Effects of
hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol, [S.l.], v. 103, n. 59, p. 899-906, 2004.
615.
HARTARD, M. et al. Comparison of the
skeletal effects of the progestogens desogestrel and levonorgestrel in oral
contraceptive preparations in young women: controlled, open, partly randomized
investigation over 13 cycles. Contraception, Stoneham , v. 74, p. 367-375, 2006.
616.
CIBULA, D. et al. Hormonal
contraception and risk of cancer. Hum.
Reprod. Update, Oxford, v. 16, n. 6, p. 631-650, 2010.
617.
HANNAFORD, P.C. et al. Mortality
among contraceptive pill users: cohort evidence from Royal College of General
Practitioners’ Oral Contraception Study. BMJ, London, v. 340, p. c927, 2010.
618.
GRIMES, D.A. et al. Progestin-only
pills for contraception. Cochrane
Database of Systematic Reviews, Oxford, Issue 1, 2010. Art. No. CD007541.
619.
KJOS, S.L. Contraception and the risk
of type 2 diabetes mellitus in latin women with prior gestational diabetes
mellitus. JAMA, Chicago, n. 280, p. 533- 538, 1998.
620.
WANNMACHER,
L. Contracepção de emergência: evidências versus preconceitos. Uso Racional de Medicamentos: temas
selecionados. Brasília, DF, v. 2, n. 6, maio 2005. Disponível em: <
http://www.opas.org.br/medicamentos/site/
621.
uploadArq/HSE_URM_COE_0505.pdf
>. Acesso em: 10 dez. 2010.
622.
VON HERTZEN, H. et al. Low dose
mifepristone and two regimens of levonorgestrel for emergency contraception: a
WHO multicentre randomised trial. Lancet, London, n. 360, p. 1803- 1810, 2002.
623.
HALPERN, V.; RAYMOND, E.G.; LOPEZ,
L.M. Repeated use of pre- and postcoital hormonal contraception for prevention
of pregnancy. Cochrane Database of
Systematic Reviews, Oxford, Issue 1, 2010. Art. No. CD007595.
624.
MARSTON, C.; MAJEED, A. Impact on
contraceptive practice of making emergency hormonal contraception available
over the counter in Great Britain: repeated cross sectional surveys. BMJ, London, v. 331, p. 271, 2005.
625.
SCHREIBER, C.A.; RATCLIFFE, S.J.;
BARNHART, K.T. A randomized controlled trial of the effect of advanced supply
of emergency contraception in postpartum teens: a feasibility study. Contraception, Stoneham, v. 81, n. 5, p. 435-440, 2010.
626.
DOUBOVA, S. V. et al. Potential
drug-drug and drug-disease interactions in prescriptions for ambulatory
patients over 50 years of age in family medicine clinics in Mexico City . BMC Health Services Research, [S. l.], v . 7. n. 147, p. 1-8, 2007.
627.
HOEFLER,
R. Interações medicamentosas. In: BRASIL. Ministério da Saúde. Secretaria de
Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência
Farmacêutica e Insumos Estratégicos. Formulário
terapêutico nacional 2008: rename 2006. Brasília: Ministério da Saúde,
2008. p. 30-33.
628.
VON BAHR, C. et al. How can drug
consumption among the elderly be improved? A systematic review. Summary and Conclusions of the SBU Report.
May 2009.
629.
VITRY, A. I. Comparative assessment
of four drug interaction compendia. Br. J. Clin. Pharmacol., Oxford, Inglaterra, v. 63, n. 6, p. 709-714, 2007.
630.
MANNHEIMER, B. et al. Natiowide
drug-dispensing data reveal important differences in adherence to drug label
recommendations on CYP2D6-dependent drug interactions. Br. J. Clin. Pharmacol., Oxford, Inglaterra, v. 69, n. 4, p. 411-417, 2010.
631.
CHATSISVILI, A. et al. Potential
drug-drug interactions in prescriptions dispensed in community pharmacies in
Greece. Pharm. World. Sci.,
[S. l.], v. 32, p. 187-193, 2010.
632.
BACIC-VRCA,
V. et al. The incidence of potential drug-drug interactions in
elderly patients with arterial hypertension. Pharm. World. Sci., [S. l.], , oct. 5, 2010. [Epub ahead of print]
633.
HOSIA-RANDELL, H. M.; MUURINEN, S.
M.; PITKÄLÄ, K. H. Exposure to potentially inappropriate drugs and drug-drug
interactions in elderly nursing home residents in Helsinki, Finland: a
cross-sectional study . Drugs Aging, Auckland, Nova Zelândia, v . 25, n. 8, p. 683-692, 2008.
634.
MOURA, C.; ACURCIO, F.; BELO, N.
Drug-drug interactions associated with length of stay and cost of
hospitalization. Pharm. Pharmaceut. Sci., [S. l.], v. 12, n. 3, p. 266-272, 2009.
635.
RIECHELMANN, R. P.; DEL GIGLD, A.
Drug interactions in oncology: how common are they? Ann. Oncol., [S. l.], v. 20, p. 1907-1912, 2009.
636.
BIBI, Z. Role of cytochrome P450 in
drug interactions. Nutrition and
Metabolism, [S. l.], v. 5, n. 27, p. 1-10, 2008.
637.
OSORIO-DE-CASTRO,
C. G. S. Interações Medicamentosas. In: FUCHS, F. D.; WANNMACHER, L.
(Eds.). Farmacologia clínica: fundamentos da terapêutica racional. 4. ed. Rio de Janeiro: Guanabara Koogan/GEN, 2010.
p.115-123.
638.
SPINA, E.; SANTORO, V.; D’ARRIGO, C.
Clinically relevant pharmacokinetic drug interactions with second-generation
antidepressants: an update. Clin. Therap., [S. l.], v. 30, n. 7, p. 1206-1227, 2008.
639.
ZHANG, L. et al. Predicting drug–drug
interactions: an FDA perspective. AAPS J., [S. l.], v. 11, n. 2, p. 300-306, 2009.
640.
PUGH, M. J. V. et al. Choice of
initial antiepileptic drug for older veterans: possible pharmacokinetic drug
interactions with existing medications. J. Am. Geriatr. Soc., [S. l.], v. 58, p. 465-471, 2010.
641.
SAITO, M., et al. A literature search
on pharmacokinetic drug interactions of statins and analysis of how such
interactions are reflected in package inserts in Japan. J. Clin. Pharm. Ther., [S. l.], v. 30, n. 1, p. 21-37, 2005.
642.
DELANEY, J. A. et al. Drug-drug
interactions between antithrombotic medications and the risk of
gastrointestinal bleeding. CMAJ, [S. l.], v. 177, n. 4, p. 347-351, 2007.
643.
GAZIANO, J. M.; GIBSON, C. M.
Potential for drug-drug interactions in patients taking analgesics for mild-to
moderate pain and low-dose aspirin for cardioprotection. Am. J. Cardiol., [S. l.], v. 97, s. 23-29, 2006.
644.
ANTHONYL, M. et al. Warfarin
interactions with substances listed in drug information compendia and in the
FDA-approved label for warfarin sodium. Clin. Pharmacol. Ther., [S. l.], v. 86, n. 41, p. 425- 429, 2009.
Nenhum comentário:
Postar um comentário